<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Adenuric, INN-febuxostat</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
	{color:#0563C1;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
strong
	{font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MGGTextLeft, li.MGGTextLeft, div.MGGTextLeft
	{mso-style-name:"MGG Text Left";
	mso-style-link:"MGG Text Left Char1";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.MGGTextLeftChar1
	{mso-style-name:"MGG Text Left Char1";
	mso-style-link:"MGG Text Left";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;
	font-family:"Calibri",sans-serif;}
 /* Page Definitions */
 @page WordSection1
	{size:596.0pt 843.0pt;
	margin:79.0pt 84.0pt 37.0pt 84.0pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:596.0pt 843.0pt;
	margin:79.0pt 57.35pt 56.75pt 84.0pt;}
div.WordSection2
	{page:WordSection2;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link="#0563C1" vlink="#954F72" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:3.1pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
I</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:3.1pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>SUMMARY
OF PRODUCT CHARACTERISTICS</span></b></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection2>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>1.       NAME OF THE MEDICINAL
PRODUCT</span></h1>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>&nbsp;</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg
film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>2.       QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Each tablet contains 80&nbsp;mg of
febuxostat. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Excipient with known effect</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Each tablet contains 236.0&nbsp;mg
of lactose</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For the full list of excipients,
see section 6.1.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Film-coated tablet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A yellow, capsule shaped, biconvex
tablet approximately 16 x 7&nbsp;mm, debossed with M on one side of the tablet
and FX3 on the other side.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.       CLINICAL PARTICULARS</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.1     Therapeutic indications</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Treatment of chronic hyperuricaemia
in conditions where urate deposition has already occurred (including a history,
or presence of, tophus and/or gouty arthritis). Febuxostat Mylan is indicated
in adults.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.2     Posology and method of
administration</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Posology</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The recommended oral dose of Febuxostat
Mylan is 80&nbsp;mg once daily without regard to food. If serum uric acid is
&gt; 6&nbsp;mg/dL (357&nbsp;µmol/L) after 2-4&nbsp;weeks, Febuxostat Mylan 120&nbsp;mg
once daily may be considered.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan works sufficiently
quickly to allow retesting of the serum uric acid after 2 weeks. The
therapeutic target is to decrease and maintain serum uric acid below 6&nbsp;mg/dL
(357&nbsp;&#956;mol/L).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gout flare prophylaxis of at least
6 months is recommended (see section 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Elderly</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is required in
the elderly (see section 5.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Renal </span></i><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>impairment</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The efficacy and safety have not
been fully evaluated in patients with severe renal impairment (creatinine
clearance &lt;30 mL/min, see section 5.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is necessary in
patients with mild or moderate renal impairment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Hepatic impairment</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>The efficacy and safety
of febuxostat has not been studied in patients with severe hepatic impairment (Child
Pugh Class C).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The recommended dose in patients
with mild hepatic impairment is 80&nbsp;mg. Limited information is available in
patients with moderate hepatic impairment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The safety and the efficacy of febuxostat
in children aged below the age of 18&nbsp;years have not been established. No
data are available.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Method of administration</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan should be taken by
mouth and can be taken with or without food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.3     Contraindications</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypersensitivity to the active
substance or to any of the excipients listed in section 6.1 (see also section
4.8).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.4     Special warnings and
precautions for use</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Cardio-vascular disorders</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Treatment with febuxostat in
patients with ischaemic heart disease or congestive heart failure is not
recommended.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A numerical greater incidence of investigator-reported
cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists
Collaboration (APTC) including cardiovascular death, non-fatal myocardial
infarction, non-fatal stroke) was observed in the febuxostat total group
compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3
events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section
5.1 for detailed characteristics of the studies). The incidence of
investigator-reported cardiovascular APTC events in the combined Phase 3
studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs.
In the long-term extension studies the incidences of investigator-reported APTC
events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol,
respectively. No statistically significant differences were found and no causal
relationship with febuxostat was established. Identified risk factors among
these patients were a medical history of atherosclerotic disease and/or
myocardial infarction, or of congestive heart failure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Medicinal product allergy /
hypersensitivity</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Rare reports of serious
allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson
Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock,
have been collected in the post-marketing experience. In most cases, these
reactions occurred during the first month of therapy with febuxostat. Some, but
not all of these patients reported renal impairment and/or previous
hypersensitivity to allopurinol. Severe hypersensitivity reactions, including
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated
with fever, haematological, renal or hepatic involvement in some cases.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients should be advised of the
signs and symptoms and monitored closely for symptoms of
allergic/hypersensitivity reactions (see section 4.8). Febuxostat treatment
should be immediately stopped if serious allergic/hypersensitivity reactions,
including Stevens-Johnson Syndrome, occur since early withdrawal is associated
with a better prognosis. If patient has developed allergic/hypersensitivity
reactions including Stevens-Johnson Syndrome and acute anaphylactic
reaction/shock, febuxostat must not be re-started in this patient at any time.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Acute gouty attacks (gout flare)</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat treatment should not be
started until an acute attack of gout has completely subsided. Gout flares may
occur during initiation of treatment due to changing serum uric acid levels
resulting in mobilization of urate from tissue deposits (see section 4.8 and
5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6
months with an NSAID or colchicine is recommended (see section 4.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If a gout flare occurs during
febuxostat treatment, it should not be discontinued. The gout flare should be
managed concurrently as appropriate for the individual patient. Continuous
treatment with febuxostat decreases frequency and intensity of gout flares.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Xanthine deposition</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In patients in whom the rate of
urate formation is greatly increased (e.g. malignant disease and its treatment,
Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in
rare cases, rise sufficiently to allow deposition in the urinary tract. As
there has been no experience with febuxostat, its use in these populations is
not recommended.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mercaptopurine/azathioprine</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat use is not recommended
in patients concomitantly treated with mercaptopurine/azathioprine as inhibition
of xanthine oxidase by febuxostat may cause increased plasma concentrations of
mercaptopurine/azathioprine that could result in severe toxicity. No
interaction studies have been performed in humans. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Where the combination cannot be
avoided, a reduction of the dose of mercaptopurine/azathioprine is recommended.
Based on modelling and simulation analysis of data from a pre-clinical study in
rats, when coadministered with febuxostat, the dose of mercaptopurine/azathioprine
should be reduced to the 20&nbsp;% or less of the previously prescribed dose in
order to avoid possible haematological effects (see section 4.5 and 5.3).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The patients should be closely
monitored and the dose of mercaptopurine/azathioprine should be subsequently
adjusted based on the evaluation of the therapeutic response and the onset of eventual
toxic effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Organ transplant recipients</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>As there has been no experience in
organ transplant recipients, the use of febuxostat in such patients is not
recommended (see section 5.1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Theophylline</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Co-administration of febuxostat 80&nbsp;mg
and theophylline 400&nbsp;mg single dose in healthy subjects showed absence of
any pharmacokinetic interaction (see section 4.5). Febuxostat 80&nbsp;mg can be
used in patients concomitantly treated with theophylline without risk of
increasing theophylline plasma levels. No data is available for febuxostat 120&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Liver disorders</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>During the combined phase 3
clinical studies, mild liver function test abnormalities were observed in
patients treated with febuxostat (5.0%). Liver function test is recommended
prior to the initiation of therapy with febuxostat and periodically thereafter
based on clinical judgment (see section 5.1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Thyroid disorders</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Increased TSH values (&gt;5.5&nbsp;µIU/mL)
were observed in patients on long-term treatment with febuxostat (5.5%) in the
long term open label extension studies. Caution is required when febuxostat is
used in patients with alteration of thyroid function (see section 5.1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Lactose</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat tablets contain lactose.
Patients with rare hereditary problems of galactose intolerance, the Lapp
lactase deficiency or glucose-galactose malabsorption should not take this
medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.5     Interaction with other
medicinal products and other forms of interaction</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mercaptopurine/azathioprine</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>On the basis of the mechanism of action
of febuxostat on XO inhibition concomitant use is not recommended. Inhibition
of XO by febuxostat may cause increased plasma concentrations of these drugs
leading to toxicity. Drug interaction studies of febuxostat with drugs (except
theophylline) that are metabolized by XO have not been performed in humans.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Modelling and simulation analysis
of data from a pre-clinical study in rats indicates that, in case of
concomitant administration with febuxostat, the dose of
mercaptopurine/azathioprine should be reduced to 20% or less of the previously
prescribed dose (see section 4.4 and 5.3)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Drug interaction studies of
febuxostat with other cytotoxic chemotherapy have not been conducted. No data
is available regarding the safety of febuxostat during other cytotoxic therapy.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Rosiglitazone/CYP2C8 substrates</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat was shown to be a weak
inhibitor of CYP2C8 <i>in vitro</i>. In a study in healthy subjects,
coadministration of 120&nbsp;mg febuxostat QD with a single 4&nbsp;mg oral dose
of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its
metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a
CYP2C8 enzyme inhibitor <i>in vivo</i>. Thus, co-administration of febuxostat
with rosiglitazone or other CYP2C8 substrates is not expected to require any
dose adjustment for those compounds.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Theophylline</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>An interaction study in healthy
subjects has been performed with febuxostat to evaluate whether the inhibition
of XO may cause an increase in the theophylline circulating levels as reported
with other XO inhibitors. The results of the study showed that the
co-administration of febuxostat 80&nbsp;mg QD with theophylline 400&nbsp;mg
single dose has no effect on the pharmacokinetics or safety of theophylline.
Therefore no special caution is advised when febuxostat 80&nbsp;mg and
theophylline are given concomitantly. No data is available for febuxostat 120&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Naproxen and other inhibitors of
glucuronidation</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat metabolism depends on
Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit
glucuronidation, such as NSAIDs and probenecid, could in theory affect the elimination
of febuxostat. In healthy subjects concomitant use of febuxostat and naproxen
250&nbsp;mg twice daily was associated with an increase in febuxostat exposure
(C<sub>max</sub> 28%, AUC 41% and t<sub>1/2 </sub>26%). In clinical studies the
use of naproxen or other NSAIDs/Cox-2 inhibitors was not related to any clinically
significant increase in adverse events.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat can be co-administered
with naproxen with no dose adjustment of febuxostat or naproxen being
necessary.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Inducers of glucuronidation</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Potent inducers of UGT enzymes
might possibly lead to increased metabolism and decreased efficacy of
febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks
after start of treatment with a potent inducer of glucuronidation. Conversely,
cessation of treatment of an inducer might lead to increased plasma levels of
febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Colchicine/indometacin/hydrochlorothiazide/warfarin</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat can be co-administered
with colchicine or indomethacin with no dose adjustment of febuxostat or the
co-administered active substance being necessary.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is necessary for
febuxostat when administered with hydrochlorothiazide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is necessary for
warfarin when administered with febuxostat. Administration of febuxostat (80&nbsp;mg
or 120&nbsp;mg once daily) with warfarin had no effect on the pharmacokinetics
of warfarin in healthy subjects. INR and Factor VII activity were also not
affected by the co- administration of febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Desipramine/CYP2D6 substrates</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat was shown to be a weak
inhibitor of CYP2D6 <i>in vitro. </i>In a study in healthy subjects, 120&nbsp;mg
febuxostat QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6
substrate indicating a potential weak inhibitory effect of febuxostat on the
CYP2D6 enzyme <i>in vivo</i>.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Thus, co-administration of
febuxostat with other CYP2D6 substrates is not expected to require any dose
adjustment for those compounds.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Antacids</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Concomitant ingestion of an antacid
containing magnesium hydroxide and aluminium hydroxide has been shown to delay
absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in C<sub>max</sub>,
but no significant change in AUC was observed. Therefore, febuxostat may be
taken without regard to antacid use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.6     Fertility, pregnancy
and lactation</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Data on a very limited number of
exposed pregnancies have not indicated any adverse effects of febuxostat on
pregnancy or on the health of the foetus/new born child. Animal studies do not
indicate direct or indirect harmful effects with respect to pregnancy,
embryonal/foetal development or parturition (see section 5.3). The potential
risk for human is unknown. Febuxostat should not be used during pregnancy.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Breast-feeding</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>It is unknown whether febuxostat is
excreted in human breast milk. Animal studies have shown excretion of this
active substance in breast milk and an impaired development of suckling pups. A
risk to a suckling infant cannot be excluded. Febuxostat should not be used
while breast-feeding.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Fertility</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In animals, reproduction studies up
to 48&nbsp;mg/kg/day showed no dose-dependent adverse effects on fertility (see
section 5.3). The effect of febuxostat on human fertility is unknown.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.7     Effects on ability to
drive and use machines</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Somnolence, dizziness, paraesthesia
and blurred vision have been reported with the use of febuxostat. Patients
should exercise caution before driving, using machinery or participating in
dangerous activities until they are reasonably certain that febuxostat does not
adversely affect performance.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.8     Undesirable effects</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The most commonly reported adverse
reactions in clinical trials (4,072 subjects treated at least with a dose from
10&nbsp;mg to 300&nbsp;mg) and post-marketing experience are gout flares, liver
function abnormalities, diarrhoea, nausea, headache, rash and oedema. These
adverse reactions were mostly mild or moderate in severity. Rare serious
hypersensitivity reactions to febuxostat, some of which were associated to
systemic symptoms, have occurred in the post-marketing experience.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Common (&#8805;1/100 to &lt;1/10),
uncommon (&#8805;1/1,000 to &lt;1/100) and rare (</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&#8805;1/10,000 to &lt;1/1,000) adverse
reactions occurring in patients treated with febuxostat are listed below.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Within each frequency grouping, adverse
reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Table 1: Adverse reactions in
combined phase 3, long-term extension studies and post-marketing experience</span></i></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood and lymphatic
  system</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Pancytopenia, <span
  style='color:black'>thrombocytopenia, agranulocytosis*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Immune system
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Anaphylactic
  reaction*, drug hypersensitivity*</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Endocrine disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood thyroid
  stimulating hormone increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Eye disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blurred vision</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Metabolism and
  nutrition</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common***</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Gout flares</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:31.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Diabetes mellitus,
  hyperlipidemia, decrease appetite, weight increase</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Weight decrease,
  increase appetite, anorexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Psychiatric disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Libido decreased,
  insomnia</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Nervousness</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Nervous system
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Headache</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.15pt;margin-right:16.8pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Dizziness,
  paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Ear and labyrinth
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Cardiac disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Atrial fibrillation,
  palpitations, ECG abnormal</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Vascular disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hypertension,
  flushing, hot flush</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Respiratory system
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Dyspnoea, bronchitis,
  upper respiratory tract infection, cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Diarrhoea**, nausea</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon:</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:6.15pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Abdominal pain,
  abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth,
  dyspepsia, constipation, frequent stools, flatulence, gastrointestinal
  discomfort</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Pancreatitis, mouth
  ulceration</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hepato-biliary
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:159.3pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Liver function
  abnormalities** <u>Uncommon</u></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Cholelithiasis</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hepatitis, jaundice*,
  liver injury*</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Skin and subcutaneous
  tissue</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:.15pt;margin-right:42.6pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rash (including
  various types of rash reported with lower frequencies, see below)</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:22.6pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Dermatitis, urticaria,
  pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash
  maculopapular, rash papular</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:35.1pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Toxic epidermal
  necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with
  eosinophilia and systemic</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>symptoms*, generalized
  rash (serious)*, erythema, exfoliative</span></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:15.3pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>rash, rash follicular,
  rash vesicular, rash pustular, rash pruritic*, rash erythematous, rash
  morbillifom, alopecia, hyperhidrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Musculoskeletal and
  connective</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>tissue disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:35.35pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Arthralgia, arthritis,
  myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle
  tightness, bursitis</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rhabdomyolysis*, joint
  stiffness, musculoskeletal stiffness</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Renal and urinary
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Renal failure,
  nephrolithiasis, haematuria, pollakiuria, proteinuria</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Tubulointerstitial
  nephritis*, micturition urgency</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Reproductive system
  and breast</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorder</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Erectile dysfunction</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>General disorders and</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>administration site
  conditions</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Oedema</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Fatigue, chest pain,
  chest discomfort</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Thirst</span></p>
  </td>
 </tr>
 <tr>
  <td width=215 valign=top style='width:161.4pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Investigations</span></p>
  </td>
  <td width=406 valign=top style='width:304.65pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood amylase
  increase, platelet count decrease, WBC decrease, lymphocyte count decrease,
  blood creatine increase, blood creatinine increase, haemoglobin decrease,
  blood urea increase, blood triglycerides increase, blood cholesterol
  increase, haematocritic decrease, blood lactate dehydrogenase increased,
  blood potassium increase</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood glucose
  increase, activated partial thromboplastin time prolonged, red blood cell
  count decrease, blood alkaline phosphatase increase, blood creatine
  phosphokinase increase*</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:11.95pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:99%;text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;line-height:99%;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>*</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>     Adverse reactions
coming from post-marketing experience</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>**   Treatment-emergent
non-infective diarrhoea and abnormal liver function tests in the combined Phase
3 studies are more frequent in patients concomitantly treated with colchicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>*** See section 5.1 for
incidences of gout flares in the individual Phase 3 randomized controlled
studies.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Rare serious hypersensitivity
reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal
necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing
experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are
characterised by progressive skin rashes associated with blisters or mucosal
lesions and eye irritation. Hypersensitivity reactions to febuxostat can be
associated to the following symptoms: skin reactions characterised by
infiltrated maculopapular eruption, generalised or exfoliative rashes, but also
skin lesions, facial oedema, fever, haematologic abnormalities such as
thrombocytopenia and eosinophilia, and single or multiple organ involvement
(liver and kidney including tubulointerstitial nephritis) (see section 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gout flares were commonly observed
soon after the start of treatment and during the first months. Thereafter, the
frequency of gout flare decreases in a time-dependent manner. Gout flare
prophylaxis is recommended (see section 4.2 and 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Reporting of suspected adverse
reactions</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Reporting suspected adverse
reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions
via the national reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-family:"Times New Roman",serif;color:windowtext'>Appendix V.</span></a></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.3pt'><span lang=EN-GB>4.9     Overdose</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients with an overdose should be
managed by symptomatic and supportive care.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.3pt'><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></h1>

<h1 style='margin-right:3.3pt'><span lang=EN-GB>&nbsp;</span></h1>

<h1 style='margin-right:3.3pt'><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pharmacotherapeutic group: Antigout
preparation, preparations inhibiting uric acid production, ATC code: M04AA03</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mechanism of action</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Uric acid is the end product of
purine metabolism in humans and is generated in the cascade of hypoxanthine
&#8594; xanthine &#8594; uric acid. Both steps in the above transformations are
catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative
that achieves its therapeutic effect of decreasing serum uric acid by
selectively inhibiting XO. Febuxostat is a potent, non-purine selective
inhibitor of XO (NP-SIXO) with an <i>in vitro</i> inhibition Ki value less than
one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized
and reduced forms of XO. At therapeutic concentrations febuxostat does not
inhibit other enzymes involved in purine or pyrimidine metabolism, namely,
guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate
phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine
nucleoside phosphorylase.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The efficacy of </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> was demonstrated in
three Phase 3 pivotal studies (the two pivotal APEX and FACT studies, and the
additional CONFIRMS study described below) that were conducted in 4101 patients
with hyperuricaemia and gout. In each phase 3 pivotal study, febuxostat
demonstrated superior ability to lower and maintain serum uric acid levels
compared to allopurinol. The primary efficacy endpoint in the APEX and FACT
studies was the proportion of patients whose last 3 monthly serum uric acid
levels were &lt; 6.0&nbsp;mg/dL (357&nbsp;µmol/L). In the additional phase 3
CONFIRMS study, for which results became available after the marketing
authorisation for febuxostat was first issued, the primary efficacy endpoint
was the proportion of patients whose serum urate level was &lt; 6.0&nbsp;mg/dL at
the final visit. No patients with organ transplant have been included in these
studies (see section 4.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>APEX Study</span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>: The Allopurinol and
Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3,
randomized, double-blind, multicenter, 28-week study. One thousand and
seventy-two (1072) patients were randomized: placebo (n=134), </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> 80&nbsp;mg QD (n=267), </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> 120&nbsp;mg QD (n=269),
</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> 240&nbsp;mg QD (n=134)
or allopurinol (300&nbsp;mg QD [n=258] for patients with a baseline serum
creatinine &#8804;1.5&nbsp;mg/dL or 100&nbsp;mg QD [n=10] for patients with a
baseline serum creatinine &gt;1.5&nbsp;mg/dL and &#8804;2.0&nbsp;mg/dL). Two
hundred and forty&nbsp;mg febuxostat (2 times the recommended highest dose) was
used as a safety evaluation dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The APEX study showed statistically
significant superiority of both the </span><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><span lang=EN-GB style='font-family:
"Times New Roman",serif'> 80&nbsp;mg QD and the </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>febuxostat</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'> 120&nbsp;mg QD treatment arms <i>versus
</i>the conventionally used doses of allopurinol 300&nbsp;mg (n = 258) /100&nbsp;mg
(n = 10) treatment arm in reducing the sUA below 6&nbsp;mg/dL (357&nbsp;µmol/L)
(see Table 2 and Figure 1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>FACT Study</span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>: The Febuxostat
Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized,
double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients
were randomized: febuxostat 80&nbsp;mg QD (n=256), febuxostat C 120&nbsp;mg QD
(n=251), or allopurinol 300&nbsp;mg QD (n=253).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The FACT study showed the
statistically significant superiority of both </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>febuxostat</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'> 80&nbsp;mg and </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> 120&nbsp;mg QD
treatment arms <i>versus </i>the conventionally used dose of allopurinol 300&nbsp;mg
treatment arm in reducing and maintaining sUA below 6&nbsp;mg/dL (357&nbsp;µmol/L).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Table 2 summarises the primary
efficacy endpoint results:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.3pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Table 2</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Proportion of Patients with Serum
Uric Acid Levels &lt;6.0&nbsp;mg/dL (357&nbsp;µmol/L) Last Three Monthly Visits</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:57.1pt;border-collapse:collapse'>
 <tr>
  <td width=117 valign=top style='width:87.6pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:27.7pt;
  margin-bottom:0in;margin-left:28.85pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Study</span></p>
  </td>
  <td width=121 valign=top style='width:90.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:0in;margin-bottom:
  0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:19.15pt;
  margin-bottom:0in;margin-left:19.95pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat
  80&nbsp;mg QD</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:0in;margin-bottom:
  0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
  style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:11.95pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:11.95pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'> 120&nbsp;mg QD</span></p>
  </td>
  <td width=128 valign=top style='width:95.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:19.15pt;
  margin-bottom:0in;margin-left:19.95pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Allopurinol</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:33.65pt;
  margin-bottom:0in;margin-left:34.5pt;text-align:center;line-height:12.45pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>300
  /</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:17.15pt;
  margin-bottom:0in;margin-left:17.8pt;text-align:center;line-height:12.85pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>100&nbsp;mg
  QD</span><sup><span lang=EN-GB style='font-family:"Times New Roman",serif'>1</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.6pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:26.35pt;
  margin-bottom:0in;margin-left:27.3pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>APEX</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:16.35pt;
  margin-bottom:0in;margin-left:17.3pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(28
  weeks)</span></p>
  </td>
  <td width=121 valign=top style='width:90.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:29.25pt;
  margin-bottom:0in;margin-left:30.4pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>48%</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>*</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:24.4pt;
  margin-bottom:0in;margin-left:25.5pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=262)</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:21.65pt;line-height:12.25pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>65%</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>*<sup>, #</sup></span></p>
  <p class=MsoNormal style='margin-top:.1pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:20.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(n=269)</span></p>
  </td>
  <td width=128 valign=top style='width:95.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:34.7pt;
  margin-bottom:0in;margin-left:35.3pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>22%</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:27.05pt;
  margin-bottom:0in;margin-left:27.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=268)</span></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.6pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:26.75pt;
  margin-bottom:0in;margin-left:27.5pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>FACT</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:16.35pt;
  margin-bottom:0in;margin-left:17.3pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(52
  weeks)</span></p>
  </td>
  <td width=121 valign=top style='width:90.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:30.1pt;
  margin-bottom:0in;margin-left:31.35pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>53%</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>*</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:24.4pt;
  margin-bottom:0in;margin-left:25.5pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=255)</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:23.15pt;
  margin-bottom:0in;margin-left:24.15pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>62%</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>*</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:17.45pt;
  margin-bottom:0in;margin-left:18.3pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=250)</span></p>
  </td>
  <td width=128 valign=top style='width:95.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:34.7pt;
  margin-bottom:0in;margin-left:35.3pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>21%</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:27.05pt;
  margin-bottom:0in;margin-left:27.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=251)</span></p>
  </td>
 </tr>
 <tr>
  <td width=117 valign=top style='width:87.6pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:17.75pt;
  margin-bottom:0in;margin-left:18.75pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Combined</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:24.4pt;
  margin-bottom:0in;margin-left:25.5pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Results</span></p>
  </td>
  <td width=121 valign=top style='width:90.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:30.25pt;
  margin-bottom:0in;margin-left:31.25pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>51%</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>*</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:24.4pt;
  margin-bottom:0in;margin-left:25.5pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=517)</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:22.5pt;line-height:12.25pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>63%</span><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>*<sup>, #</sup></span></p>
  <p class=MsoNormal style='margin-top:.1pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:20.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(n=519)</span></p>
  </td>
  <td width=128 valign=top style='width:95.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:34.6pt;
  margin-bottom:0in;margin-left:35.45pt;text-align:center;line-height:12.3pt;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>22%</span></p>
  <p class=MsoNormal align=center style='margin-top:.05pt;margin-right:27.05pt;
  margin-bottom:0in;margin-left:27.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=519)</span></p>
  </td>
 </tr>
 <tr>
  <td width=468 colspan=4 valign=top style='width:350.65pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:6.3pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>1</span></sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'> results from subjects
  receiving either 100&nbsp;mg QD (n=10: patients with serum creatinine &gt;1.5
  and </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#8804;2.0&nbsp;mg/dL)
  or 300&nbsp;mg QD (n=509) were pooled </span><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>for analyses.</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>* p &lt; 0.001 vs
  allopurinol, # p &lt; 0.001 vs 80&nbsp;mg</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The ability of febuxostat to lower
serum uric acid levels was prompt and persistent. Reduction in serum uric acid
level to &lt;6.0&nbsp;mg/dL (357&nbsp;µmol/L) was noted by the Week 2 visit and
was maintained throughout treatment. The mean serum uric acid levels over time
for each treatment group from the two pivotal Phase 3 studies are shown in
Figure 1.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Figure 1 Mean Serum Uric
Acid Levels in Combined Pivotal Phase 3 Studies</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:98.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span style='position:absolute;z-index:-1895828992;left:0px;margin-left:
234px;margin-top:8px;width:344px;height:262px'><img width=344 height=262
src="Febuxostat%20Mylan%20not%20most%20recent_files/image001.png"></span><span
lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>11</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:98.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span style='position:absolute;z-index:-1895827968;left:0px;margin-left:
254px;margin-top:5px;width:308px;height:209px'><img width=308 height=209
src="Febuxostat%20Mylan%20not%20most%20recent_files/image002.png"></span><span
style='position:relative;z-index:-1895826944'><span style='left:0px;position:
absolute;left:195px;top:-1px;width:13px;height:204px'><img width=13 height=204
src="Febuxostat%20Mylan%20not%20most%20recent_files/image003.png"
alt="Mean (±SEM) Serum Uric Acid Level (mg/dL)"></span></span><span lang=EN-GB
style='font-size:8.0pt;font-family:"Times New Roman",serif'>10                                                                       </span><span
lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Placebo</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:8.5pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>9</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>8</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>7                                                                       </span><span
lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Allopurinol</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>6</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:260.5pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Febuxostat
80&nbsp;mg</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:5.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>5</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>4</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:260.5pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Febuxostat
120&nbsp;mg</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:7.5pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>3               <u>
 </u></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:7.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:260.5pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Febuxostat
240&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>2</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:123.6pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>BL  
2     4     6     8    12   16   20   24   28   32   36   40   44   48   52</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:8.5pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:210.8pt;
margin-bottom:0in;margin-left:230.0pt;text-align:center;line-height:normal;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB style='font-size:
8.0pt;font-family:"Times New Roman",serif'>Week</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:6.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:114.4pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>BL=baseline      
SEM=standard error of the mean</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Note: 509 patients received
allopurinol 300&nbsp;mg QD; 10 patients with serum creatinine &gt;1.5 and &#8804;2.0&nbsp;mg/dL
were dosed with 100&nbsp;mg QD. (10 patients out of 268 in APEX study).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>240&nbsp;mg febuxostat was used to
evaluate the safety of febuxostat at twice the recommended highest dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>CONFIRMS Study: The CONFIRMS study
was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and
efficacy of febuxostat 40&nbsp;mg and 80&nbsp;mg, in comparison with
allopurinol 300&nbsp;mg or 200&nbsp;mg, in patients with gout and
hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were
randomized: febuxostat 40&nbsp;mg QD (n=757), febuxostat 80&nbsp;mg QD (n=756),
or allopurinol 300/200&nbsp;mg QD (n=756). At least 65% of the patients had
mild-moderate renal impairment (with creatinine clearance of 30-89&nbsp;mL/min).
Prophylaxis against gout flares was obligatory over the 26-week period.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The proportion of patients with
serum urate levels of &lt; 6.0&nbsp;mg/dL (357&nbsp;µmol/L) at the final visit,
was 45% for 40&nbsp;mg febuxostat, 67% for febuxostat 80&nbsp;mg and 42% for
allopurinol 300/200&nbsp;mg, respectively.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Primary endpoint in the sub-group
of patients with renal impairment</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The APEX Study evaluated efficacy
in 40 patients with renal impairment (i.e., baseline serum creatinine &gt; 1.5&nbsp;mg/dL
and &#8804;2.0&nbsp;mg/dL). For renally impaired subjects who were randomized
to allopurinol, the dose was capped at 100&nbsp;mg QD. Febuxostat achieved the
primary efficacy endpoint in 44% (80&nbsp;mg QD), 45% (120&nbsp;mg QD), and 60%
(240&nbsp;mg QD) of patients compared to 0% in the allopurinol 100&nbsp;mg QD
and placebo groups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There were no clinically
significant differences in the percent decrease in serum uric acid
concentration in healthy subjects irrespective of their renal function (58% in
the normal renal function group and 55% in the severe renal dysfunction group).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>An analysis in patients with gout
and renal impairment was prospectively defined in the CONFIRMS study, and
showed that febuxostat was significantly more efficacious in lowering serum
urate levels to &lt; 6&nbsp;mg/dL compared to allopurinol 300&nbsp;mg/200&nbsp;mg
in patients who had gout with mild to moderate renal impairment (65% of
patients studied).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Primary endpoint in the sub group
of patients with sUA &#8805; 10&nbsp;mg/dL</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Approximately 40% of patients
(combined APEX and FACT) had a baseline sUA of &#8805; 10&nbsp;mg/dL. In this
subgroup </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> achieved the primary
efficacy endpoint (sUA &lt; 6.0&nbsp;mg/dL at the last 3 visits) in 41% (80&nbsp;mg
QD), 48% (120&nbsp;mg QD), and 66% (240&nbsp;mg QD) of patients compared to 9%
in the allopurinol 300&nbsp;mg/100&nbsp;mg QD and 0% in the placebo groups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In the CONFIRMS study, the
proportion of patients achieving the primary efficacy endpoint (sUA &lt;6.0&nbsp;mg/dL
at the final visit) for patients with a baseline serum urate level of &#8805;
10&nbsp;mg/dL treated with febuxostat 40&nbsp;mg QD was 27% (66/249), with
febuxostat 80&nbsp;mg QD 49% (125/254) and with allopurinol 300&nbsp;mg/200&nbsp;mg
QD 31% (72/230), respectively.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Clinical Outcomes: proportion of
patients requiring treatment for a gout flare</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>APEX study: During the 8-week
prophylaxis period, a greater proportion of subjects in the febuxostat 120&nbsp;mg
(36%) treatment group required treatment for gout flare compared to febuxostat
80&nbsp;mg (28%), allopurinol 300&nbsp;mg (23%) and placebo (20%). Flares
increased following the prophylaxis period and gradually decreased over time. Between
46% and 55% of subjects received treatment for gout flares from Week 8 and Week
28. Gout flares during the last 4 weeks of the study (Weeks 24-28) were
observed in 15% (febuxostat 80, 120&nbsp;mg), 14% (allopurinol 300&nbsp;mg) and
20% (placebo) of subjects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>FACT study: During the 8-week
prophylaxis period, a greater proportion of subjects in the febuxostat 120&nbsp;mg
(36%) treatment group required treatment for a gout flare compared to both the
febuxostat 80&nbsp;mg (22%) and allopurinol 300&nbsp;mg (21%) treatment groups.
After the 8-week prophylaxis period, the incidences of flares increased and
gradually decreased over time (64% and 70% of subjects received treatment for
gout flares from Week 8-52). Gout flares during the last 4 weeks of the study (Weeks
49-52) were observed in 6-8% (febuxostat 80&nbsp;mg, 120&nbsp;mg) and 11%
(allopurinol 300&nbsp;mg) of subjects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The proportion of subjects
requiring treatment for a gout flare (APEX and FACT Study) was numerically
lower in the groups that achieved an average post-baseline serum urate level
&lt;6.0&nbsp;mg/dL, &lt;5.0&nbsp;mg/dL, or &lt;4.0&nbsp;mg/dL compared to the
group that achieved an average post-baseline serum urate level &#8805;6.0&nbsp;mg/dL
during the last 32 weeks of the treatment period (Week 20 - Week 24 to Week 49
- 52 intervals).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>During the CONFIRMS study, the
percentages of patients who required treatment for gout flares (Day 1 through
Month 6) were 31% and 25% for the febuxostat 80&nbsp;mg and allopurinol groups,
respectively. No difference in the proportion of patients requiring treatment
for gout flares was observed between the febuxostat 80&nbsp;mg and 40&nbsp;mg
groups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Long-term, open label extension
Studies</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EXCEL Study (C02-021): The Excel
study was a three years Phase 3, open label, multicenter, randomised,
allopurinol-controlled, safety extension study for patients who had completed
the pivotal Phase 3 studies (APEX or FACT).  A total of 1,086 patients were
enrolled: </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> 80&nbsp;mg QD (n=649), </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> 120&nbsp;mg QD (n=292)
and allopurinol 300/100&nbsp;mg QD (n=145). About 69% of patients required no
treatment change to achieve a final stable treatment. Patients who had 3
consecutive sUA levels &gt;6.0&nbsp;mg/dL were withdrawn.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Serum urate levels were maintained
over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80&nbsp;mg
and 120&nbsp;mg, respectively, had sUA &lt;6&nbsp;mg/dL at Month 36).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Three years data showed a decrease
in the incidence of gout flares with less than 4% of patients requiring
treatment for a flare (i.e. more than 96% of patients did not require treatment
for a flare) at Month 16-24 and at Month 30-36.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>46% and 38%, of patients on final
stable treatment of febuxostat 80 or 120&nbsp;mg QD, respectively, had complete
resolution of the primary palpable tophus from baseline to the Final Visit.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>FOCUS Study (TMX-01-005) was a 5
years Phase 2, open-label, multicenter, safety extension study for patients who
had completed the febuxostat 4 weeks of double blind dosing in study
TMX-00-004.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>116 patients were enrolled and
received initially febuxostat 80&nbsp;mg QD. 62% of patients required no dose
adjustment to maintain sUA &lt;6&nbsp;mg/dL and 38% of patients required a dose
adjustment to achieve a final stable dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The proportion of patients with
serum urate levels of &lt;6.0&nbsp;mg/dL (357&nbsp;µmol/L) at the final visit
was greater than 80% (81-100%) at each febuxostat dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>During the phase 3 clinical
studies, mild liver function test abnormalities were observed in patients
treated with febuxostat (5.0%). These rates were similar to the rates reported
on allopurinol (4.2%) (see section 4.4). Increased TSH values (&gt;5.5&nbsp;µIU/mL)
were observed in patients on long-term treatment with febuxostat (5.5%) and
patients with allopurinol (5.8%) in the long term open label extension studies
(see section 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>5.2     Pharmacokinetic
properties</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In healthy subjects, maximum plasma
concentrations (C<sub>max</sub>) and area under the plasma concentration time
curve (AUC) of febuxostat increased in a dose proportional manner following
single and multiple doses of 10&nbsp;mg to 120&nbsp;mg. For doses between 120&nbsp;mg
and 300&nbsp;mg, a greater than dose proportional increase in AUC is observed
for febuxostat. There is no appreciable accumulation when doses of 10&nbsp;mg
to 240&nbsp;mg are administered every 24 hours. Febuxostat has an apparent mean
terminal elimination half-life (t<sub>1/2</sub>) of approximately 5 to 8 hours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Population
pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with
hyperuricaemia and gout, treated with febuxostat 40-240&nbsp;mg QD. In general,
febuxostat pharmacokinetic parameters estimated by these analyses are
consistent with those obtained from healthy subjects, indicating that healthy
subjects are representative for pharmacokinetic/pharmacodynamic assessment in
the patient population with gout.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Absorption</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat is rapidly (t<sub>max</sub>
of 1.0-1.5 h) and well absorbed (at least 84%). After single or multiple oral 80
and 120&nbsp;mg once daily doses, C<sub>max</sub> is approximately 2.8-3.2&nbsp;µg/mL,
and 5.0-5.3&nbsp;µg/mL, respectively. Absolute bioavailability of the
febuxostat tablet formulation has not been studied.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple oral 80&nbsp;mg
once daily doses or a single 120&nbsp;mg dose with a high fat meal, there was a
49% and 38% decrease in C<sub>max</sub> and an 18% and 16% decrease in AUC,
respectively. However, no clinically significant change in the percent decrease
in serum uric acid concentration was observed where tested (80&nbsp;mg multiple
dose). Thus, </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> may be taken without
regard to food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Distribution</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The apparent steady state volume of
distribution (Vss/F) of febuxostat ranges from 29 to 75 L after oral doses of
10-300&nbsp;mg. The plasma protein binding of febuxostat is approximately
99.2%, (primarily to albumin), and is constant over the concentration range
achieved with 80 and 120&nbsp;mg doses. Plasma protein binding of the active
metabolites ranges from about 82% to 91%.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Biotransformation</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat is extensively
metabolized by conjugation <i>via </i>uridine diphosphate glucuronosyltransferase
(UDPGT) enzyme system and oxidation <i>via </i>the cytochrome P450 (CYP)
system. Four pharmacologically active hydroxyl metabolites have been
identified, of which three occur in plasma of humans. <i>In vitro </i>studies
with human liver microsomes showed that those oxidative metabolites were formed
primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and febuxostat glucuronide was formed
mainly by UGT 1A1, 1A8, and 1A9.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Elimination</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat is eliminated by both
hepatic and renal pathways. Following an 80&nbsp;mg oral dose of <sup>14</sup>C-labeled
febuxostat, approximately 49% of the dose was recovered in the urine as
unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%),
its known oxidative metabolites and their conjugates (13%), and other unknown
metabolites (3%). In addition to the urinary excretion, approximately 45% of
the dose was recovered in the faeces as the unchanged febuxostat (12%), the
acyl glucuronide of the active substance (1%), its known oxidative metabolites
and their conjugates (25%), and other unknown metabolites (7%).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Renal impairment</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple doses of 80&nbsp;mg
of febuxostat in patients with mild, moderate or severe renal impairment, the C<sub>max</sub>
of febuxostat did not change, relative to subjects with normal renal function.
The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5&nbsp;µg</span><span
lang=EN-GB style='font-family:"Cambria Math",serif'>&#8901;</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>h/mL in the normal renal
function group to 13.2&nbsp;µg.h/mL in the severe renal dysfunction group. The
C<sub>max</sub> and AUC of active metabolites increased up to 2- and 4-fold,
respectively. However, no dose adjustment is necessary in patients with mild or
moderate renal impairment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hepatic impairment</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple doses of 80&nbsp;mg
of </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> in patients with mild
(Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, the C<sub>max</sub>
and AUC of febuxostat and its metabolites did not change significantly compared
to subjects with normal hepatic function. No studies have been conducted in
patients with severe hepatic impairment (Child-Pugh Class C).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Age</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There were no significant changes
observed in AUC of febuxostat or its metabolites following multiple oral doses
of febuxostat in elderly as compared to younger healthy subjects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gender</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple oral doses of </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>, the C<sub>max</sub>
and AUC were 24% and 12% higher in females than in males, respectively.
However, weight-corrected C<sub>max</sub> and AUC were similar between the
genders. No dose adjustment is needed based on gender.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>5.3     Preclinical safety data</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Effects in non-clinical studies
were generally observed at exposures in excess of the maximum human exposure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pharmacokinetic modelling and
simulation of rat data suggests that, when co-administered with febuxostat, the
clinical dose of mercaptopurine/azathioprine should be reduced to 20% or less
of the previously prescribed dose in order to avoid possible haematological
effects (see section 4.4 and 4.5).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Carcinogenesis, mutagenesis,
impairment of fertility</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In male rats, a statistically
significant increase in urinary bladder tumours (transitional cell papilloma
and carcinoma) was found only in association with xanthine calculi in the high
dose group, at approximately 11 times human exposure. There was no significant
increase in any other tumour type in either male or female mice or rats. These
findings are considered a consequence of species specific purine metabolism and
urine composition and of no relevance to clinical use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A standard battery of test for
genotoxicity did not reveal any biologically relevant genotoxic effects for
febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat at oral doses up to 48&nbsp;mg/kg/day
was found to have no effect on fertility and reproductive performance of male
and female rats.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There was no evidence of impaired
fertility, teratogenic effects, or harm to the foetus due to febuxostat. There
was high dose maternal toxicity accompanied by a reduction in weaning index and
reduced development of offspring in rats at approximately 4.3 times human
exposure. Teratology studies, performed in pregnant rats at approximately 4.3
times and pregnant rabbits at approximately</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13 times human exposure did not
reveal any teratogenic effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.       PHARMACEUTICAL
PARTICULARS</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.1     List of excipients</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tablet core</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Lactose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Microcrystalline cellulose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Magnesium stearate</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hydroxypropylcellulose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Croscarmellose sodium</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Colloidal hydrated silica</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Colloidal anhydrous silica</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Crospovidone</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Talc</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tablet coating</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypromellose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Titanium dioxide (E171) </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Ethylcellulose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Iron oxide yellow (E172)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Triacetin</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Iron oxide black (E172)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.2     Incompatibilities</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Not applicable.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.3     Shelf life</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2 years.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For bottles: After first opening
use within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.4     Special precautions for
storage</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>This medicinal product does not
require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.5     Nature and contents of
container</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>(PVC/oPA/Alu)/Alu (desiccant
embedded) blisters of 14, 28, 84 tablets, calendar blisters of 28, 84 tablets and
perforated unit dose blisters of 28 x 1 tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>(PVC/oPA/Alu)/Alu blisters of 14,
28, 42 tablets, calendar blisters of 28 tablets and perforated unit dose
blisters of 28 x 1 tablets and multipacks of 84 (2 packs of 42) tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>HDPE bottle with polypropylene (PP)
screw cap closure with desiccant containing 28 or 84 tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>6.6     Special precautions for
disposal</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No special requirements.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.5pt;page-break-after:auto'><span lang=EN-GB
style='font-weight:normal'>&nbsp;</span></h1>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>7.       MARKETING
AUTHORISATION HOLDER</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Mylan
S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>117
Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>69
800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>8.       MARKETING
AUTHORISATION NUMBER(S)</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/001</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/002</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/003</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/004</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/005</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/006</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/007</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/008</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/017</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/018</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/019</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/020</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/021</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/022</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Date of first authorisation: </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:6.4pt'><span lang=EN-GB>10.     DATE OF REVISION OF THE
TEXT</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Detailed information on this
medicinal product is available on the website of the European Medicines Agency </span><span
lang=EN-GB><a href="http://www.ema.europa.eu/"><span style='font-family:"Times New Roman",serif;
color:windowtext'>http://www.ema.europa.eu</span></a></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt;page-break-before:always'><span lang=EN-GB>1<span
class=Heading1Char>.         NAME OF THE MEDICINAL PRODUCT</span></span></h1>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>&nbsp;</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg
film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>2.         QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Each tablet contains 120&nbsp;mg of
febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Excipient with known effect</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Each tablet contains 354.0&nbsp;mg
of lactose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For the full list of excipients,
see section 6.1.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>3.         PHARMACEUTICAL FORM</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Film-coated tablet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A yellow, capsule shaped, biconvex
tablet, approximately 18 x 8 mm, debossed with M on one side of the tablet and
FX4 on the other side.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.         CLINICAL PARTICULARS</span></h1>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>&nbsp;</span></h1>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.1       Therapeutic indications</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan is indicated for
the treatment of chronic hyperuricaemia in conditions where urate deposition
has already occurred (including a history, or presence of, tophus and/or gouty
arthritis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan is indicated for
the prevention and treatment of hyperuricaemia in adult patients undergoing
chemotherapy for haematologic malignancies at intermediate to high risk of
Tumor Lysis Syndrome (TLS).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan is indicated in
adults.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.2       Posology and method
of administration</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Posology</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gout</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The recommended oral dose of Febuxostat
Mylan is 80&nbsp;mg once daily without regard to food. If serum uric acid is
&gt; 6&nbsp;mg/dL (357&nbsp;µmol/L) after 2-4 weeks, Febuxostat Mylan 120&nbsp;mg
once daily may be considered.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan works sufficiently
quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic
target is to decrease and maintain serum uric acid below 6&nbsp;mg/dL (357&nbsp;&#956;mol/L).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gout flare prophylaxis of at least
6 months is recommended (see section 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tumor Lysis Syndrome</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The recommended oral dose of Febuxostat
Mylan is 120&nbsp;mg once daily without regard to food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan should be started
two days before the beginning of cytotoxic therapy and continued for a minimum
of 7 days; however treatment may be prolonged up to 9 days according to
chemotherapy duration as per clinical judgment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Elderly</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is required in
the elderly (see section 5.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Renal impairment</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The efficacy and safety have not
been fully evaluated in patients with severe renal impairment (creatinine
clearance &lt;30 mL/min, see section 5.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is necessary in
patients with mild or moderate renal impairment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hepatic impairment</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The efficacy and safety of
febuxostat has not been studied in patients with severe hepatic impairment (Child
Pugh Class C).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gout: The recommended dose in
patients with mild hepatic impairment is 80&nbsp;mg. Limited information is
available in patients with moderate hepatic impairment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tumour Lysis Syndrome: in the pivotal
Phase III trial (FLORENCE) only subjects with severe hepatic insufficiency were
excluded from trial participation. No dose adjustment was required for enrolled
patients on the basis of hepatic function.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The safety and the efficacy of febuxostat
in children aged below the age of 18 years have not been established. No data
are available.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Method of administration</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Oral use</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan should be taken by
mouth and can be taken with or without food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.3       Contraindications</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypersensitivity to the active
substance or to any of the excipients listed in section 6.1 (see also section
4.8).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.4       Special warnings and
precautions for use</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Cardio-vascular disorders</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Treatment of chronic hyperuricaemia</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Treatment with febuxostat in
patients with ischaemic heart disease or congestive heart failure is not
recommended. A numerical greater incidence of investigator-reported
cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists
Collaboration (APTC) including cardiovascular death, non-fatal myocardial
infarction, non-fatal stroke) was observed in the febuxostat total group
compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3
events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section
5.1 for detailed characteristics of the studies). The incidence of
investigator-reported cardiovascular APTC events in the combined Phase 3
studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs.
In the long-term extension studies the incidences of investigator-reported APTC
events were 1.2 and 0.6 events per 100&nbsp;PYs for febuxostat and allopurinol,
respectively. No statistically significant differences were found and no causal
relationship with febuxostat was established. Identified risk factors among
these patients were a medical history of atherosclerotic disease and/or
myocardial infarction, or of congestive heart failure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Prevention and treatment of
hyperuricaemia in patients at risk of TLS</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients undergoing chemotherapy
for haematologic malignancies at intermediate to high risk of Tumor Lysis
Syndrome treated with febuxostat should be under cardiac monitoring as
clinically appropriate.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Medicinal product allergy /
hypersensitivity</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Rare reports of serious
allergic/hypersensitivity reactions, including life-threatening Stevens-Johnson
Syndrome, Toxic epidermal necrolysis and acute anaphylactic reaction/shock,
have been collected in the post-marketing experience. In most cases, these
reactions occurred during the first month of therapy with febuxostat. Some, but
not all of these patients reported renal impairment and/or previous
hypersensitivity to allopurinol. Severe hypersensitivity reactions, including
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) were associated
with fever, haematological, renal or hepatic involvement in some cases.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients should be advised of the
signs and symptoms and monitored closely for symptoms of allergic/hypersensitivity
reactions (see section 4.8). Febuxostat treatment should be immediately stopped
if serious allergic/hypersensitivity reactions, including Stevens-Johnson
Syndrome, occur since early withdrawal is associated with a better prognosis.
If patient has developed allergic/hypersensitivity reactions including
Stevens-Johnson Syndrome and acute anaphylactic reaction/shock, febuxostat must
not be re-started in this patient at any time.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Acute gouty attacks (gout flare)</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat treatment should not be
started until an acute attack of gout has completely subsided. Gout flares may
occur during initiation of treatment due to changing serum uric acid levels
resulting in mobilization of urate from tissue deposits (see sections 4.8 and
5.1). At treatment initiation with febuxostat flare prophylaxis for at least 6
months with an NSAID or colchicine is recommended (see section 4.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If a gout flare occurs during
febuxostat treatment, it should not be discontinued. The gout flare should be
managed concurrently as appropriate for the individual patient. Continuous
treatment with febuxostat decreases frequency and intensity of gout flares.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Xanthine deposition</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In patients in whom the rate of
urate formation is greatly increased (e.g. malignant disease and its treatment,
Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in
rare cases, rise sufficiently to allow deposition in the urinary tract. This
has not been observed in the pivotal clinical study with febuxostat in the
Tumor Lysis Syndrome. As there has been no experience with febuxostat, its use
in patients with Lesch-Nyhan Syndrome is not recommended.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mercaptopurine/azathioprine</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat use is not recommended
in patients concomitantly treated with mercaptopurine/azathioprine as inhibition
of xanthine oxidase by febuxostat may cause increased plasma concentrations of
mercaptopurine/azathioprine that could result in severe toxicity. No
interaction studies have been performed in humans.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Where the combination cannot be
avoided, a reduction of the dose of mercaptopurine/azathioprine is recommended.
Based on modelling and simulation analysis of data from a pre-clinical study in
rats, when coadministered with febuxostat, the dose of
mercaptopurine/azathioprine should be reduced to the 20% or less of the
previously prescribed dose in order to avoid possible haematological effects
(see section 4.5 and 5.3).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The patients should be closely monitored
and the dose of mercaptopurine/azathioprine should be subsequently adjusted
based on the evaluation of the therapeutic response and the onset of eventual
toxic effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Organ transplant recipients</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>As there has been no experience in
organ transplant recipients, the use of febuxostat in such patients is not
recommended (see section 5.1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Theophylline</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Co-administration of febuxostat 80&nbsp;mg
and theophylline 400&nbsp;mg single dose in healthy subjects showed absence of
any pharmacokinetic interaction (see section 4.5). Febuxostat 80&nbsp;mg can be
used in patients concomitantly treated with theophylline without risk of
increasing theophylline plasma levels.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No data is available for febuxostat
120&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Liver disorders</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>During the combined phase 3 clinical
studies, mild liver function test abnormalities were observed in patients
treated with febuxostat (5.0%). Liver function test is recommended prior to the
initiation of therapy with febuxostat and periodically thereafter based on
clinical judgment (see section 5.1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Thyroid disorders</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Increased TSH values (&gt;5.5&nbsp;µIU/mL)
were observed in patients on long-term treatment with febuxostat (5.5%) in the
long term open label extension studies. Caution is required when febuxostat is
used in patients with alteration of thyroid function (see section 5.1).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Lactose</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat tablets contain lactose.
Patients with rare hereditary problems of galactose intolerance, the Lapp
lactase deficiency or glucose-galactose malabsorption should not take this
medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.5       Interaction with
other medicinal products and other forms of interaction</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mercaptopurine/azathioprine</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>On the basis of the mechanism of
action of febuxostat on XO inhibition concomitant use is not recommended.
Inhibition of XO by febuxostat may cause increased plasma concentrations of
these drugs leading to toxicity. Drug interaction studies of febuxostat with
drugs (except theophylline) that are metabolized by XO have not been performed
in humans.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Modelling and simulation analysis
of data from a pre-clinical study in rats, indicates that, in case of
concomitant administration with febuxostat, the dose of
mercaptopurine/azathioprine should be reduced to the 20% or less of the
previously prescribed dose (see section 4.4 and 5.3).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Drug interaction studies of
febuxostat with other cytotoxic chemotherapy have not been conducted. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In the Tumor Lysis Syndrome pivotal
trial febuxostat 120&nbsp;mg daily was administered to patients undergoing
several chemotherapy regimens, including monoclonal antibodies. However,
drug-drug and drug-disease interactions were not explored during this study.
Therefore, possible interactions with any concomitantly administered cytotoxic
drug cannot be ruled out.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Rosiglitazone/CYP2C8 substrates</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat was shown to be a weak inhibitor
of CYP2C8 <i>in vitro. </i>In a study in healthy subjects, coadministration of
120&nbsp;mg febuxostat QD with a single 4&nbsp;mg oral dose of rosiglitazone
had no effect on the pharmacokinetics of rosiglitazone and its metabolite
N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme
inhibitor <i>in vivo</i>. Thus, co-administration of febuxostat with rosiglitazone
or other CYP2C8 substrates is not expected to require any dose adjustment for
those compounds.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Theophylline</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>An interaction study in healthy
subjects has been performed with febuxostat to evaluate whether the inhibition
of XO may cause an increase in the theophylline circulating levels as reported
with other XO inhibitors. The results of the study showed that the
co-administration of febuxostat 80&nbsp;mg QD with theophylline 400&nbsp;mg
single dose has no effect on the pharmacokinetics or safety of theophylline.
Therefore no special caution is advised when febuxostat 80&nbsp;mg and
theophylline are given concomitantly. No data is available for febuxostat 120&nbsp;mg.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Naproxen and other inhibitors of
glucuronidation</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat metabolism depends on
Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit
glucuronidation, such as NSAIDs and probenecid, could in theory affect the
elimination of febuxostat. In healthy subjects concomitant use of febuxostat
and naproxen 250&nbsp;mg twice daily was associated with an increase in
febuxostat exposure (C<sub>max</sub> 28%, AUC 41% and t<sub>1/2</sub> 26%). In
clinical studies the use of naproxen or other NSAIDs/Cox-2 inhibitors was not
related to any clinically significant increase in adverse events.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat can be co-administered
with naproxen with no dose adjustment of febuxostat or naproxen being
necessary.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Inducers of glucuronidation</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Potent inducers of UGT enzymes
might possibly lead to increased metabolism and decreased efficacy of
febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks
after start of treatment with a potent inducer of glucuronidation. Conversely,
cessation of treatment of an inducer might lead to increased plasma levels of
febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Colchicine/indometacin/hydrochlorothiazide/warfarin</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat can be co-administered
with colchicine or indomethacin with no dose adjustment of febuxostat or the
co-administered active substance being necessary.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is necessary for
febuxostat when administered with hydrochlorothiazide.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No dose adjustment is necessary for
warfarin when administered with febuxostat. Administration of febuxostat (80&nbsp;mg
or 120&nbsp;mg once daily) with warfarin had no effect on the pharmacokinetics
of warfarin in healthy subjects. INR and Factor VII activity were also not
affected by the co-administration of febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Desipramine/CYP2D6 substrates</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat was shown to be a weak
inhibitor of CYP2D6 <i>in vitro. </i>In a study in healthy subjects, 120&nbsp;mg
febuxostat QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6
substrate indicating a potential weak inhibitory effect of febuxostat on the
CYP2D6 enzyme <i>in vivo</i>. Thus, co-administration of febuxostat with other CYP2D6
substrates is not expected to require any dose adjustment for those compounds.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Antacids</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Concomitant ingestion of an antacid
containing magnesium hydroxide and aluminium hydroxide has been shown to delay
absorption of febuxostat (approximately 1 hour) and to cause a 32% decrease in C<sub>max</sub>,
but no significant change in AUC was observed. Therefore, febuxostat may be
taken without regard to antacid use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.6       Fertility, pregnancy
and lactation</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pregnancy</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Data on a very limited number of
exposed pregnancies have not indicated any adverse effects of febuxostat on
pregnancy or on the health of the foetus/new born child. Animal studies do not
indicate direct or indirect harmful effects with respect to pregnancy,
embryonal/foetal development or parturition (see section 5.3). The potential
risk for human is unknown. Febuxostat should not be used during pregnancy.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Breast-feeding</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>It is unknown whether febuxostat is
excreted in human breast milk. Animal studies have shown excretion of this
active substance in breast milk and an impaired development of suckling pups. A
risk to a suckling infant cannot be excluded. Febuxostat should not be used
while breast-feeding.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Fertility</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In animals, reproduction studies up
to 48&nbsp;mg/kg/day showed no dose-dependent adverse effects on fertility (see
section 5.3). The effect of febuxostat on human fertility is unknown.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.7       Effects on ability to
drive and use machines</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Somnolence, dizziness, paraesthesia
and blurred vision have been reported with the use of febuxostat. Patients
should exercise caution before driving, using machinery or participating in
dangerous activities until they are reasonably certain that febuxostat does not
adversely affect performance.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:3.1pt'><span lang=EN-GB>4.8       Undesirable effects</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Summary of the safety profile</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The most commonly reported adverse
reactions in clinical trials (4,072 subjects treated at least with a dose from
10&nbsp;mg to 300&nbsp;mg) and post-marketing experience in gout patients are
gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash
and oedema. These adverse reactions were mostly mild or moderate in severity.
Rare serious hypersensitivity reactions to febuxostat, some of which were
associated to systemic symptoms, have occurred in the post-marketing experience.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Common (&#8805;1/100 to &lt;1/10),
uncommon (&#8805;1/1,000 to &lt;1/100) and rare (&#8805;1/10,000 to
&lt;1/1,000) adverse reactions occurring in patients treated with febuxostat
are listed below.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The frequencies are based on studies
and post-marketing experience in gout patients.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Within each frequency grouping,
adverse reactions are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Table 1: Adverse
reactions in combined phase 3, long-term extension studies and post-marketing
experience in gout patients.</span></i></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:.25pt;border-collapse:collapse'>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;page-break-after:avoid;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Blood and
  lymphatic system</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;page-break-after:avoid;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;page-break-after:avoid;text-autospace:
  none'><u><span lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;page-break-after:avoid;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Pancytopenia,
  <span style='color:black'>thrombocytopenia, agranulocytosis*</span></span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Immune system
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Anaphylactic
  reaction*, drug hypersensitivity*</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Endocrine disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood thyroid stimulating
  hormone increased</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Eye disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blurred vision</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Metabolism and
  nutrition</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common***</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Gout flares</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:31.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Diabetes mellitus,
  hyperlipidemia, decrease appetite, weight increase</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Weight decrease,
  increase appetite, anorexia</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Psychiatric disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Libido decreased,
  insomnia</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Nervousness</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Nervous system
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Headache</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:16.8pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Dizziness,
  paraesthesia, hemiparesis, somnolence, altered taste, hypoaesthesia, hyposmia</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Ear and labyrinth disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Tinnitus</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Cardiac disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:244.6pt;margin-bottom:
  0in;margin-left:5.0pt;text-align:justify;line-height:12.3pt;text-autospace:
  none'><u><span lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:4.4pt;margin-bottom:
  0in;margin-left:5.0pt;text-align:justify;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Atrial
  fibrillation, palpitations, ECG abnormal, left bundle branch block (see
  section Tumor Lysis Syndrome), sinus tachycardia (see section Tumor Lysis
  Syndrome)</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Vascular disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hypertension,
  flushing, hot flush, haemorrhage (see section Tumor Lysis Syndrome)</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Respiratory system
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Dyspnoea, bronchitis,
  upper respiratory tract infection, cough</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Diarrhoea**, nausea</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon:</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:6.15pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Abdominal pain,
  abdominal distension, gastro-oesophageal reflux disease, vomiting, dry mouth,
  dyspepsia, constipation, frequent stools, flatulence, gastrointestinal
  discomfort</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Pancreatitis, mouth
  ulceration</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hepato-biliary
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:159.3pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Liver function
  abnormalities** <u>Uncommon</u></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.45pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Cholelithiasis</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Hepatitis, jaundice*,
  liver injury*</span></p>
  </td>
 </tr>
 <tr style='height:151.95pt'>
  <td width=217 valign=top style='width:163.05pt;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:151.95pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.4pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Skin and subcutaneous
  tissue</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border:none;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:151.95pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:.15pt;margin-right:42.6pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rash (including
  various types of rash reported with lower frequencies, see below)</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:22.6pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Dermatitis, urticaria,
  pruritus, skin discolouration, skin lesion, petechiae, rash macular, rash
  maculopapular, rash papular</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.4pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.15pt;margin-right:35.1pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Toxic epidermal
  necrolysis*, Stevens-Johnson Syndrome*, angioedema*, drug reaction with
  eosinophilia and systemic symptoms*, generalized rash (serious)*, erythema,
  exfoliative rash, rash follicular, rash vesicular, rash pustular, rash
  pruritic*, rash erythematous, rash morbillifom, alopecia, hyperhidrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Musculoskeletal and
  connective</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>tissue disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:35.4pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Arthralgia, arthritis,
  myalgia, musculoskeletal pain, muscle weakness, muscle spasm, muscle
  tightness, bursitis</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rhabdomyolysis*, joint
  stiffness, musculoskeletal stiffness</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Renal and urinary
  disorders</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Renal failure,
  nephrolithiasis, haematuria, pollakiuria, proteinuria</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Tubulointerstitial
  nephritis*, micturition urgency</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Reproductive system
  and breast</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>disorder</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Erectile dysfunction</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>General disorders and</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>administration site
  conditions</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Common</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Oedema</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Fatigue, chest pain,
  chest discomfort</span></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:normal;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Thirst</span></p>
  </td>
 </tr>
 <tr>
  <td width=217 valign=top style='width:163.05pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:12.3pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Investigations</span></p>
  </td>
  <td width=406 valign=top style='width:304.75pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.3pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:11.95pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood amylase
  increase, platelet count decrease, WBC decrease, lymphocyte count decrease,
  blood creatine increase, blood creatinine increase, haemoglobin decrease,
  blood urea increase, blood triglycerides increase, blood cholesterol
  increase, haematocritic decrease, blood lactate dehydrogenase increased,
  blood potassium increase</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.6pt;text-autospace:none'><u><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Rare</span></u></p>
  <p class=MsoNormal style='margin-top:.05pt;margin-right:21.05pt;margin-bottom:
  0in;margin-left:5.0pt;line-height:12.7pt;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Blood glucose
  increased, activated partial thromboplastin time prolonged, red blood cell
  count decrease, blood alkaline phosphatase increase, blood creatine
  phosphokinase increase*</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>*</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>     Adverse reactions
coming from post-marketing experience</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>**   Treatment-emergent
non-infective diarrhoea and abnormal liver function tests in the combined Phase
3 studies are more frequent in patients concomitantly treated with colchicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:21.3pt;text-indent:-21.3pt;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>*** See section 5.1 for
incidences of gout flares in the individual Phase 3 randomized controlled
studies.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Description of selected adverse
reactions</span></u></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.7pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.7pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Rare serious hypersensitivity
reactions to febuxostat, including Stevens-Johnson Syndrome, Toxic epidermal
necrolysis and anaphylactic reaction/shock, have occurred in the post-marketing
experience. Stevens-Johnson Syndrome and Toxic epidermal necrolysis are
characterised by progressive skin rashes associated with blisters or mucosal
lesions and eye irritation. Hypersensitivity reactions to febuxostat can be
associated to the following symptoms: skin reactions characterised by
infiltrated maculopapular eruption, generalised or exfoliative rashes, but also
skin lesions, facial oedema, fever, haematologic abnormalities such as
thrombocytopenia and eosinophilia, and single or multiple organ involvement
(liver and kidney including tubulointerstitial nephritis) (see section 4.4).</span></p>

<p class=MsoNormal style='margin-top:.65pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gout flares were commonly observed
soon after the start of treatment and during the first months. Thereafter, the
frequency of gout flare decreases in a time-dependent manner. Gout flare
prophylaxis is recommended (see section 4.2 and 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tumor Lysis Syndrome</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Summary of the safety
profile</span></u></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.7pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.7pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In the randomized, double-blind,
Phase 3 pivotal FLORENCE (FLO-01) study comparing febuxostat with allopurinol
(346 patients undergoing chemotherapy for haematologic malignancies and at intermediate-to-high
risk of TLS), only 22 (6.4%) patients overall experienced adverse reactions, namely
11 (6.4%) patients in each treatment group. The majority of adverse reactions
were either mild or moderate.</span></p>

<p class=MsoNormal style='margin-top:.25pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.6pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.45pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Overall, the FLORENCE trial did not
highlight any particular safety concern in addition to the previous experience
with febuxostat in gout, with the exception of the following three adverse
reactions (listed above in table 1).</span></p>

<p class=MsoNormal style='margin-top:.55pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Cardiac disorders:</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.6pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Uncommon: Left bundle branch block,
sinus tachycardia</span></p>

<p class=MsoNormal style='margin-top:.65pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:100%;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Vascular disorders:</span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'> </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:100%;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Uncommon: haemorrhage</span></p>

<p class=MsoNormal style='margin-top:.55pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Reporting of suspected adverse
reactions</span></u></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:99%;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:.05pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:99%;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Reporting suspected adverse
reactions after authorisation of the medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions
via the national reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-family:"Times New Roman",serif;color:windowtext'>Appendix V</span><span
style='font-family:"Times New Roman",serif;color:windowtext;text-decoration:
none'>.</span></a></span></p>

<p class=MsoNormal style='margin-top:.9pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4.9      Overdose</span></b></p>

<p class=MsoNormal style='margin-top:.45pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Patients with an overdose should be
managed by symptomatic and supportive care.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5.        PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='margin-top:.65pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5.1      Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='margin-top:.45pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pharmacotherapeutic group: Antigout
preparation, preparations inhibiting uric acid production, ATC code: M04AA03</span></p>

<p class=MsoNormal style='margin-top:.7pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.45pt;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mechanism of action</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.45pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.45pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Uric acid is the end product of
purine metabolism in humans and is generated in the cascade of hypoxanthine
&#8594; xanthine &#8594; uric acid. Both steps in the above transformations are
catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative
that achieves its therapeutic effect of decreasing serum uric acid by
selectively inhibiting XO. Febuxostat is a potent, non-purine selective
inhibitor of XO (NP-SIXO) with an <i>in vitro</i> inhibition Ki value less than
one nanomolar. Febuxostat has been shown to potently inhibit both the oxidized
and reduced forms of XO. At therapeutic concentrations febuxostat does not
inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine
deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate
phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine
nucleoside phosphorylase.</span></p>

<p class=MsoNormal style='margin-top:.9pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:13.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.45pt;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal style='margin-top:.15pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:11.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.6pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.45pt;text-autospace:none'><i><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Gout</span></u></i></p>

<p class=MsoNormal style='margin-top:.3pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:11.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.6pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The efficacy of febuxostat was
demonstrated in three Phase 3 pivotal studies (the two pivotal APEX and FACT
studies, and the additional CONFIRMS study, described below) that were
conducted in 4101 patients with hyperuricaemia and gout. In each phase 3
pivotal study, febuxostat demonstrated superior ability to lower and maintain
serum uric acid levels compared to allopurinol. The primary efficacy endpoint
in the APEX and FACT studies was the proportion of patients whose last 3 monthly
serum uric acid levels were &lt; 6.0&nbsp;mg/dL (357&nbsp;µmol/L). In the
additional phase 3 CONFIRMS study, for which results became available after the
marketing authorisation for febuxostat was first issued, the primary efficacy
endpoint was the proportion of patients whose serum urate level was &lt; 6.0&nbsp;mg/dL
at the final visit. No patients with organ transplant have been included in
these studies (see section 4.2).</span></p>

<p class=MsoNormal style='margin-top:.7pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>APEX Study</span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>: The Allopurinol and
Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3,
randomized, double-blind, multicenter, 28-week study. One thousand and
seventy-two (1072) patients were randomized: placebo (n=134), febuxostat 80&nbsp;mg
QD (n=267), febuxostat 120&nbsp;mg QD (n=269), febuxostat 240&nbsp;mg QD
(n=134) or allopurinol (300&nbsp;mg QD [n=258] for patients with a baseline
serum creatinine &#8804;1.5&nbsp;mg/dL or 100&nbsp;mg QD [n=10] for patients
with a baseline serum creatinine &gt;1.5&nbsp;mg/dL and &#8804;2.0&nbsp;mg/dL).
Two hundred and forty&nbsp;mg febuxostat (2 times the recommended highest dose)
was used as a safety evaluation dose.</span></p>

<p class=MsoNormal style='margin-top:.85pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:12.6pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The APEX study showed statistically
significant superiority of both the febuxostat 80&nbsp;mg QD and the febuxostat
120&nbsp;mg QD treatment arms <i>versus </i>the conventionally used doses of
allopurinol 300&nbsp;mg (n=258) /100&nbsp;mg (n = 10) treatment arm in reducing
the sUA below 6&nbsp;mg/dL (357&nbsp;µmol/L) (see Table 2 and Figure 1).</span></p>

<p class=MsoNormal style='margin-top:.55pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:99%;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>FACT Study</span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>: The Febuxostat
Allopurinol Controlled Trial (FACT) Study was a Phase 3, randomized,
double-blind, multicenter, 52-week study. Seven hundred sixty (760) patients
were randomized: febuxostat 80&nbsp;mg QD (n=256), febuxostat 120&nbsp;mg QD
(n=251), or allopurinol 300&nbsp;mg QD (n=253).</span></p>

<p class=MsoNormal style='margin-top:.65pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The FACT study showed the
statistically significant superiority of both febuxostat 80&nbsp;mg and febuxostat
120&nbsp;mg QD treatment arms <i>versus </i>the conventionally used dose of
allopurinol 300&nbsp;mg treatment arm in reducing and maintaining sUA below 6&nbsp;mg/dL
(357&nbsp;µmol/L).</span></p>

<p class=MsoNormal style='margin-top:.65pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Table 2 summarises the primary
efficacy endpoint results:</span></p>

<p class=MsoNormal style='margin-top:.9pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.0pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:3.1pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Table 2</span></b></p>

<p class=MsoNormal style='margin-top:.1pt;margin-right:3.1pt;margin-bottom:
0in;margin-left:0in;line-height:12.6pt;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Proportion of Patients
with Serum Uric Acid Levels &lt;6.0&nbsp;mg/dL (357&nbsp;µmol/L) Last Three
Monthly Visits</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='margin-left:57.0pt;border-collapse:collapse'>
 <tr>
  <td width=120 valign=top style='width:89.9pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:28.9pt;
  margin-bottom:0in;margin-left:29.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Study</span></p>
  </td>
  <td width=121 valign=top style='width:90.7pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:19.25pt;
  margin-bottom:0in;margin-left:19.85pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat
  </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>80&nbsp;mg
  QD</span></p>
  </td>
  <td width=102 valign=top style='width:76.45pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-bottom:0in;line-height:normal;text-autospace:
  none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:9.55pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:11.95pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>120&nbsp;mg QD</span></p>
  </td>
  <td width=120 valign=top style='width:90.2pt;border:solid black 1.0pt;
  border-left:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:18.05pt;
  margin-bottom:0in;margin-left:19.0pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Allopurinol</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:32.55pt;
  margin-bottom:0in;margin-left:33.5pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>300
  /</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:16.05pt;
  margin-bottom:0in;margin-left:16.85pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>100&nbsp;mg
  QD<sup>1</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:89.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:27.55pt;
  margin-bottom:0in;margin-left:28.35pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>APEX</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:17.55pt;
  margin-bottom:0in;margin-left:18.4pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(28
  weeks)</span></p>
  </td>
  <td width=121 valign=top style='width:90.7pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:29.4pt;
  margin-bottom:0in;margin-left:30.25pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>48%*</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:24.55pt;
  margin-bottom:0in;margin-left:25.35pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=262)</span></p>
  </td>
  <td width=102 valign=top style='width:76.45pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:21.65pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>65%*<sup>, #</sup></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:20.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(n=269)</span></p>
  </td>
  <td width=120 valign=top style='width:90.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:33.65pt;
  margin-bottom:0in;margin-left:34.35pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>22%</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:25.95pt;
  margin-bottom:0in;margin-left:26.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=268)</span></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:89.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:27.95pt;
  margin-bottom:0in;margin-left:28.6pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>FACT</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:17.55pt;
  margin-bottom:0in;margin-left:18.4pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(52
  weeks)</span></p>
  </td>
  <td width=121 valign=top style='width:90.7pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:30.25pt;
  margin-bottom:0in;margin-left:31.25pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>53%*</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:24.55pt;
  margin-bottom:0in;margin-left:25.35pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=255)</span></p>
  </td>
  <td width=102 valign=top style='width:76.45pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:23.05pt;
  margin-bottom:0in;margin-left:24.15pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>62%*</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:17.35pt;
  margin-bottom:0in;margin-left:18.3pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=250)</span></p>
  </td>
  <td width=120 valign=top style='width:90.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:33.65pt;
  margin-bottom:0in;margin-left:34.35pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>21%</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:25.95pt;
  margin-bottom:0in;margin-left:26.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=251)</span></p>
  </td>
 </tr>
 <tr>
  <td width=120 valign=top style='width:89.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:18.95pt;
  margin-bottom:0in;margin-left:19.85pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Combined</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:25.6pt;
  margin-bottom:0in;margin-left:26.55pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Results</span></p>
  </td>
  <td width=121 valign=top style='width:90.7pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:30.35pt;
  margin-bottom:0in;margin-left:31.1pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>51%*</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:24.55pt;
  margin-bottom:0in;margin-left:25.35pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=517)</span></p>
  </td>
  <td width=102 valign=top style='width:76.45pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:22.5pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>63%*<sup>, #</sup></span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:20.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>(n=519)</span></p>
  </td>
  <td width=120 valign=top style='width:90.2pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:33.5pt;
  margin-bottom:0in;margin-left:34.45pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>22%</span></p>
  <p class=MsoNormal align=center style='margin-top:0in;margin-right:25.95pt;
  margin-bottom:0in;margin-left:26.9pt;text-align:center;line-height:normal;
  text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>(n=519)</span></p>
  </td>
 </tr>
 <tr>
  <td width=463 colspan=4 valign=top style='width:347.25pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=MsoNormal style='margin-top:0in;margin-right:6.5pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>1</span></sup><span
  lang=EN-GB style='font-family:"Times New Roman",serif'> results from subjects
  receiving either 100&nbsp;mg QD (n=10: patients with serum creatinine &gt;1.5
  and </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>&#8804;2.0&nbsp;mg/dL)
  or 300&nbsp;mg QD (n=509) were pooled </span><span lang=EN-GB
  style='font-family:"Times New Roman",serif'>for analyses.</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:5.1pt;line-height:normal;text-autospace:none'><span
  lang=EN-GB style='font-family:"Times New Roman",serif'>* p &lt; 0.001 vs
  allopurinol, # p &lt; 0.001 vs 80&nbsp;mg</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:5.9pt;line-height:12.3pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:5.9pt;line-height:12.3pt;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The ability of </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> to lower serum uric
acid levels was prompt and persistent. Reduction in serum uric acid level to
&lt;6.0&nbsp;mg/dL (357&nbsp;µmol/L) was noted by the Week 2 visit and was
maintained throughout treatment. The mean serum uric acid levels over time for
each treatment group from the two pivotal Phase 3 studies are shown in Figure
1.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:5.9pt;line-height:12.45pt;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:3.5pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:53.3pt;line-height:12.45pt;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Figure 1
Mean Serum Uric Acid Levels in Combined Pivotal Phase 3 Studies</span></b></p>

<p class=MsoNormal style='margin-top:.1pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:12.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.9pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:98.75pt;line-height:9.0pt;page-break-after:avoid;text-autospace:
none'><span style='position:absolute;z-index:-1895825920;left:0px;margin-left:
234px;margin-top:8px;width:344px;height:262px'><img width=344 height=262
src="Febuxostat%20Mylan%20not%20most%20recent_files/image004.png"></span><span
lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>11</span></p>

<p class=MsoNormal style='margin-top:.5pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.75pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:98.75pt;line-height:11.2pt;page-break-after:avoid;text-autospace:
none'><span style='position:absolute;z-index:-1895823872;left:0px;margin-left:
254px;margin-top:5px;width:308px;height:209px'><img width=308 height=209
src="Febuxostat%20Mylan%20not%20most%20recent_files/image002.png"></span><span
style='position:relative;z-index:-1895822848'><span style='left:0px;position:
absolute;left:195px;top:-1px;width:13px;height:204px'><img width=13 height=204
src="Febuxostat%20Mylan%20not%20most%20recent_files/image005.png"
alt="Mean (±SEM) Serum Uric Acid Level (mg/dL)"></span></span><span lang=EN-GB
style='font-size:8.0pt;font-family:"Times New Roman",serif'>10                                                                       </span><span
lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Placebo</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:8.5pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:8.5pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.9pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:9.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>9</span></p>

<p class=MsoNormal style='margin-top:.5pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.9pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:9.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>8</span></p>

<p class=MsoNormal style='margin-top:.5pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.9pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:9.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>7                                                                       </span><span
lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Allopurinol</span></p>

<p class=MsoNormal style='margin-top:.5pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.9pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>6</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:260.5pt;line-height:6.8pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Febuxostat
80&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:.45pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:5.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:5.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:9.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>5</span></p>

<p class=MsoNormal style='margin-top:.5pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:10.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:10.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.9pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:8.25pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>4</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:260.5pt;line-height:5.3pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Febuxostat
120&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:.35pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:7.5pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:7.5pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:9.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>3               <u>
 </u></span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:7.0pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:7.0pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:260.5pt;line-height:6.7pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>Febuxostat
240&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:102.75pt;line-height:7.15pt;page-break-after:avoid;text-autospace:
none'><span style='position:absolute;z-index:-1895824896;left:0px;margin-left:
577px;margin-top:5px;width:1px;height:4px'><img width=1 height=4
src="Febuxostat%20Mylan%20not%20most%20recent_files/image006.png"></span><span
lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>2</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:123.6pt;line-height:7.15pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:8.0pt;font-family:"Times New Roman",serif'>BL  
2     4     6     8    12   16   20   24   28   32   36   40   44   48   52</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:8.5pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-size:8.5pt;font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:210.8pt;
margin-bottom:0in;margin-left:230.0pt;text-align:center;line-height:9.0pt;
page-break-after:avoid;text-autospace:none'><span lang=EN-GB style='font-size:
8.0pt;font-family:"Times New Roman",serif'>Week</span></p>

<p class=MsoNormal style='margin-top:.25pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:6.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
0in;margin-left:114.4pt;line-height:6.8pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:6.0pt;font-family:"Times New Roman",serif'>BL=baseline      
SEM=standard error of the mean</span></p>

<p class=MsoNormal style='margin-top:.6pt;margin-right:0in;margin-bottom:0in;
margin-left:0in;line-height:11.0pt;page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:1.6pt;margin-right:-1.0pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Note: 509
patients received allopurinol 300&nbsp;mg QD; 10 patients with serum creatinine
&gt;1.5 and &#8804;2.0&nbsp;mg/dL were dosed with 100&nbsp;mg QD. (10 patients
out of 268 in APEX study).<br>
240&nbsp;mg febuxostat was used to evaluate the safety of febuxostat at twice
the recommended highest dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>CONFIRMS Study: The CONFIRMS study
was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and
efficacy of febuxostat 40&nbsp;mg and 80&nbsp;mg, in comparison with
allopurinol 300&nbsp;mg or 200&nbsp;mg, in patients with gout and
hyperuricaemia. Two thousand and two hundred-sixty nine (2269) patients were
randomized: febuxostat 40&nbsp;mg QD (n=757), </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>febuxostat </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>80&nbsp;mg QD (n=756), or
allopurinol 300/200&nbsp;mg QD (n=756). At least 65% of the patients had
mild-moderate renal impairment (with creatinine clearance of 30-89 mL/min).
Prophylaxis against gout flares was obligatory over the 26-week period.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The proportion of patients with
serum urate levels of &lt; 6.0&nbsp;mg/dL (357&nbsp;µmol/L) at the final visit,
was 45% for 40&nbsp;mg febuxostat, 67% for febuxostat 80&nbsp;mg and 42% for
allopurinol 300/200&nbsp;mg, respectively.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Primary endpoint in the sub-group
of patients with renal impairment</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The APEX Study evaluated efficacy
in 40 patients with renal impairment (i.e., baseline serum creatinine &gt; 1.5&nbsp;mg/dL
and &#8804;2.0&nbsp;mg/dL). For renally impaired subjects who were randomized
to allopurinol, the dose was capped at 100&nbsp;mg QD. Febuxostat achieved the
primary efficacy endpoint in 44% (80&nbsp;mg QD), 45% (120&nbsp;mg QD), and 60%
(240&nbsp;mg QD) of patients compared to 0% in the allopurinol 100&nbsp;mg QD
and placebo groups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There were no clinically
significant differences in the percent decrease in serum uric acid
concentration in healthy subjects irrespective of their renal function (58% in
the normal renal function group and 55% in the severe renal dysfunction group).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>An analysis in patients with gout
and renal impairment was prospectively defined in the CONFIRMS study, and
showed that febuxostat was significantly more efficacious in lowering serum
urate levels to &lt; 6&nbsp;mg/dL compared to allopurinol 300&nbsp;mg/200&nbsp;mg
in patients who had gout with mild to moderate renal impairment (65% of
patients studied).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Primary endpoint in the sub group
of patients with sUA &#8805; 10&nbsp;mg/dL</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Approximately 40% of patients
(combined APEX and FACT) had a baseline sUA of &#8805; 10&nbsp;mg/dL. In this
subgroup febuxostat achieved the primary efficacy endpoint (sUA &lt; 6.0&nbsp;mg/dL
at the last 3 visits) in 41% (80&nbsp;mg QD), 48% (120&nbsp;mg QD), and 66%
(240&nbsp;mg QD) of patients compared to 9% in the allopurinol 300&nbsp;mg/100&nbsp;mg
QD and 0% in the placebo groups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In the CONFIRMS study, the
proportion of patients achieving the primary efficacy endpoint (sUA &lt;6.0&nbsp;mg/dL
at the final visit) for patients with a baseline serum urate level of &#8805;
10&nbsp;mg/dL treated with febuxostat 40&nbsp;mg QD was 27% (66/249), with
febuxostat 80&nbsp;mg QD 49% (125/254) and with allopurinol 300&nbsp;mg/200&nbsp;mg
QD 31% (72/230), respectively.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Clinical Outcomes: proportion of
patients requiring treatment for a gout flare</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Apex study: During the 8-week
prophylaxis period, a greater proportion of subjects in the febuxostat 120&nbsp;mg
(36%) treatment group required treatment for gout flare compared to febuxostat
80&nbsp;mg (28%), allopurinol 300&nbsp;mg (23%) and placebo (20%). Flares
increased following the prophylaxis period and gradually decreased over time.
Between 46% and 55% of subjects received treatment for gout flares from Week 8
and Week 28. Gout flares during the last 4 weeks of the study (Weeks 24-28)
were observed in 15% (febuxostat 80, 120&nbsp;mg), 14% (allopurinol 300&nbsp;mg)
and 20% (placebo) of subjects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Fact study: During the 8-week
prophylaxis period, a greater proportion of subjects in the febuxostat 120&nbsp;mg
(36%) treatment group required treatment for a gout flare compared to both the
febuxostat 80&nbsp;mg (22%) and allopurinol 300&nbsp;mg (21%) treatment groups.
After the 8-week prophylaxis period, the incidences of flares increased and
gradually decreased over time (64% and 70% of subjects received treatment for
gout flares from Week 8-52). Gout flares during the last 4 weeks of the study
(Weeks 49-52) were observed in 6-8% (febuxostat 80&nbsp;mg, 120&nbsp;mg) and
11% (allopurinol 300&nbsp;mg) of subjects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The proportion of subjects
requiring treatment for a gout flare (APEX and FACT Study) was numerically
lower in the groups that achieved an average post-baseline serum urate level
&lt;6.0&nbsp;mg/dL, &lt;5.0&nbsp;mg/dL, or &lt;4.0&nbsp;mg/dL compared to the
group that achieved an average post-baseline serum urate level &#8805;6.0&nbsp;mg/dL
during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 -
52 intervals).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>During the CONFIRMS study, the
percentages of patients who required treatment for gout flares (Day 1 through
Month 6) were 31% and 25% for the febuxostat 80&nbsp;mg and allopurinol groups,
respectively. No difference in the proportion of patients requiring treatment
for gout flares was observed between the febuxostat 80&nbsp;mg and 40&nbsp;mg
groups.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Long-term, open label extension
Studies</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EXCEL Study (C02-021): The Excel
study was a three years Phase 3, open label, multicenter, randomised,
allopurinol-controlled, safety extension study for patients who had completed
the pivotal Phase 3 studies (APEX or FACT). A total of 1,086 patients were
enrolled: Febuxostat 80&nbsp;mg QD (n=649), febuxostat 120&nbsp;mg QD (n=292)
and allopurinol 300/100&nbsp;mg QD (n=145). About 69% of patients required no
treatment change to achieve a final stable treatment. Patients who had 3 consecutive
sUA levels &gt;6.0&nbsp;mg/dL were withdrawn.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Serum urate levels were maintained
over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80&nbsp;mg
and 120&nbsp;mg, respectively, had sUA &lt;6&nbsp;mg/dL at Month 36).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Three years data showed a decrease
in the incidence of gout flares with less than 4% of patients requiring
treatment for a flare (i.e. more than 96% of patients did not require treatment
for a flare) at Month 16-24 and at Month 30-36.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>46% and 38%, of patients on final
stable treatment of febuxostat 80 or 120&nbsp;mg QD, respectively, had complete
resolution of the primary palpable tophus from baseline to the Final Visit.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>FOCUS Study (TMX-01-005) was a 5
years Phase 2, open-label, multicenter, safety extension study for patients who
had completed the febuxostat 4 weeks of double blind dosing in study
TMX-00-004. 116 patients were enrolled and received initially febuxostat 80&nbsp;mg
QD. 62% of patients required no dose adjustment to maintain sUA &lt;6&nbsp;mg/dL
and 38% of patients required a dose adjustment to achieve a final stable dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The proportion of patients with
serum urate levels of &lt;6.0&nbsp;mg/dL (357&nbsp;µmol/L) at the final visit
was greater than 80% (81-100%) at each febuxostat dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>During the phase 3 clinical
studies, mild liver function test abnormalities were observed in patients treated
with febuxostat (5.0%). These rates were similar to the rates reported on
allopurinol (4.2%) (see section 4.4). Increased TSH values (&gt;5.5&nbsp;µIU/mL)
were observed in patients on long-term treatment with febuxostat (5.5%) and
patients with allopurinol (5.8%) in the long term open label extension studies
(see section 4.4).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:13.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><i><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tumor Lysis Syndrome</span></u></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The efficacy and safety of febuxostat
in the prevention and treatment of Tumor Lysis Syndrome was evaluated in the
FLORENCE (FLO-01) study. Febuxostat C showed a superior and faster urate
lowering activity compared to allopurinol.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>FLORENCE was a randomized (1:1),
double blind, phase III, pivotal trial comparing febuxostat 120&nbsp;mg once
daily with allopurinol 200 to 600&nbsp;mg daily (mean allopurinol daily dose [±
standard deviation]: 349.7 ± 112.90&nbsp;mg) in terms of control of serum uric
acid level. Eligible patients had to be candidates for allopurinol treatment or
have no access to rasburicase. Primary endpoints were serum uric acid area
under the curve (AUC sUA</span><span lang=EN-GB style='font-size:7.0pt;
font-family:"Times New Roman",serif'>1-8</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>) and change in serum creatinine
(sC) level both from baseline to Day 8.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Overall, 346 patients with
haematological malignancies undergoing chemotherapy and at intermediate/high
risk of Tumor Lysis Syndrome were included. Mean AUC sUA</span><span
lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman",serif'>1-8 </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(mgxh/dl) was
significantly lower with febuxostat (514.0 ± 225.71 vs 708.0 ± 234.42; least
square means difference: -196.794 [95% confidence interval: -238.600 ;
-154.988]; p &lt; .0001). Furthermore, the mean serum uric acid level was
significantly lower with febuxostat since the first 24 hours of treatment and
at any following time point. No significant difference in mean serum creatinine
change (%) occurred between febuxostat and allopurinol (-0.83 ± 26.98 vs -4.92
± 16.70 respectively; least square means difference: 4.0970 [95% confidence
interval: -0.6467 ; 8.8406]; p=0.0903). With regard to secondary endpoints, no
significant difference was detected in terms of incidence of laboratory TLS
(8.1% and 9.2% in febuxostat and allopurinol arm, respectively; relative risk:
0.875 [95% confidence interval: 0.4408 ; 1.7369]; p=0.8488) nor of clinical TLS
(1.7% and 1.2% in febuxostat and allopurinol arm, respectively; relative risk:
0.994 [95% confidence interval: 0.9691 ; 1.0199]; p=1.0000).  Incidence of overall
treatment-emergent signs and symptoms and adverse drug reactions was 67.6% vs
64.7% and 6.4% vs 6.4% with febuxostat and allopurinol respectively. In the
FLORENCE study febuxostat demonstrated a superior control of serum uric acid level
compared to allopurinol in patients scheduled to receive the latter drug. No
data comparing febuxostat with rasburicase are currently available. The
efficacy and safety of febuxostat has not been established in patients with
acute severe TLS, e.g. in patients who failed on other urate lowering
therapies.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5.2      Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In healthy subjects, maximum plasma
concentrations (C</span><span lang=EN-GB style='font-size:7.0pt;font-family:
"Times New Roman",serif'>max</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>)
and area under the plasma concentration time curve (AUC) of febuxostat
increased in a dose proportional manner following single and multiple doses of
10&nbsp;mg to 120&nbsp;mg. For doses between 120&nbsp;mg and 300&nbsp;mg, a
greater than dose proportional increase in AUC is observed for febuxostat.
There is no appreciable accumulation when doses of 10&nbsp;mg to 240&nbsp;mg
are administered every 24 hours. Febuxostat has an apparent mean terminal
elimination half-life (t<sub>1/2</sub>) of approximately 5 to 8 hours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Population
pharmacokinetic/pharmacodynamic analyses were conducted in 211 patients with
hyperuricaemia and gout, treated with febuxostat 40-240&nbsp;mg QD. In general,
febuxostat pharmacokinetic parameters estimated by these analyses are
consistent with those obtained from healthy subjects, indicating that healthy
subjects are representative for pharmacokinetic/pharmacodynamic assessment in
the patient population with gout.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Absorption</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat is rapidly (t</span><span
lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman",serif'>max </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>of 1.0-1.5 h) and well
absorbed (at least 84%). After single or multiple oral 80 and 120&nbsp;mg once
daily doses, C</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman",serif'>max
</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>is
approximately 2.8-3.2&nbsp;µg/mL, and 5.0-5.3&nbsp;µg/mL, respectively.
Absolute bioavailability of the febuxostat tablet formulation has not been
studied.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple oral 80&nbsp;mg
once daily doses or a single 120&nbsp;mg dose with a high fat meal, there was a
49% and 38% decrease in C</span><span lang=EN-GB style='font-size:7.0pt;
font-family:"Times New Roman",serif'>max </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>and a 18% and 16% decrease in AUC,
respectively. However, no clinically significant change in the percent decrease
in serum uric acid concentration was observed where tested (80&nbsp;mg multiple
dose). Thus, febuxostat may be taken without regard to food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Distribution</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The apparent steady state volume of
distribution (V</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman",serif'>ss</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>/F) of febuxostat ranges
from 29 to 75 L after oral doses of 10-300&nbsp;mg. The plasma protein binding
of febuxostat is approximately 99.2%, (primarily to albumin), and is constant
over the concentration range achieved with 80 and 120&nbsp;mg doses. Plasma
protein binding of the active metabolites ranges from about 82% to 91%.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Biotransformation</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat is extensively
metabolized by conjugation <i>via </i>uridine diphosphate
glucuronosyltransferase (UDPGT) enzyme system and oxidation <i>via </i>the
cytochrome P450 (CYP) system. Four pharmacologically active hydroxyl
metabolites have been identified, of which three occur in plasma of humans. <i>In
vitro </i>studies with human liver microsomes showed that those oxidative
metabolites were formed primarily by CYP1A1, CYP1A2, CYP2C8 or CYP2C9 and
febuxostat glucuronide was formed mainly by UGT 1A1, 1A8, and 1A9.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Elimination</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat is eliminated by both
hepatic and renal pathways. Following an 80&nbsp;mg oral dose of <sup>14</sup>C-
labeled febuxostat, approximately 49% of the dose was recovered in the urine as
unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%),
its known oxidative metabolites and their conjugates (13%), and other unknown metabolites
(3%). In addition to the urinary excretion, approximately 45% of the dose was
recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide
of the active substance (1%), its known oxidative metabolites and their
conjugates (25%), and other unknown metabolites (7%).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Renal impairment</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple doses of 80&nbsp;mg
of febuxostat in patients with mild, moderate or severe renal impairment, the C<sub>max</sub>
of febuxostat did not change, relative to subjects with normal renal function.
The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5&nbsp;µg</span><span
lang=EN-GB style='font-family:"Cambria Math",serif'>&#8901;</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>h/mL in the normal renal
function group to 13.2&nbsp;µg.h/mL in the severe renal dysfunction group. The
C<sub>max</sub> and AUC of active metabolites increased up to 2- and 4-fold, respectively.
However, no dose adjustment is necessary in patients with mild or moderate
renal impairment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hepatic impairment</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple doses of 80&nbsp;mg
of febuxostat in patients with mild (Child-Pugh Class A) or moderate
(Child-Pugh Class B) hepatic impairment, the C</span><span lang=EN-GB
style='font-size:7.0pt;font-family:"Times New Roman",serif'>max </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>and AUC of febuxostat
and its metabolites did not change significantly compared to subjects with
normal hepatic function. No studies have been conducted in patients with severe
hepatic impairment (Child-Pugh Class C).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Age</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There were no significant changes
observed in AUC of febuxostat or its metabolites following multiple oral doses
of febuxostat in elderly as compared to younger healthy subjects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Gender</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Following multiple oral doses of febuxostat,
the C</span><span lang=EN-GB style='font-size:7.0pt;font-family:"Times New Roman",serif'>max
</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>and AUC
were 24% and 12% higher in females than in males, respectively. However,
weight-corrected C</span><span lang=EN-GB style='font-size:7.0pt;font-family:
"Times New Roman",serif'>max </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>and
AUC were similar between the genders. No dose adjustment is needed based on
gender.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5.3      Preclinical safety data</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Effects in non-clinical studies
were generally observed at exposures in excess of the maximum human exposure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pharmacokinetic modelling and
simulation of rat data suggests that, when co-administered with febuxostat, the
clinical dose of mercaptopurine/azathioprine should be reduced to 20% or less
of the previously prescribed dose in order to avoid possible haematological
effects (see section 4.4 and 4.5).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Carcinogenesis, mutagenesis,
impairment of fertility</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In male rats, a statistically
significant increase in urinary bladder tumours (transitional cell papilloma
and carcinoma) was found only in association with xanthine calculi in the high
dose group, at approximately 11 times human exposure. There was no significant
increase in any other tumour type in either male or female mice or rats. These
findings are considered a consequence of species specific purine metabolism and
urine composition and of no relevance to clinical use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>A standard battery of test for
genotoxicity did not reveal any biologically relevant genotoxic effects for febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat at oral doses up to 48&nbsp;mg/kg/day
was found to have no effect on fertility and reproductive performance of male
and female rats.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There was no evidence of impaired
fertility, teratogenic effects, or harm to the foetus due to febuxostat. There
was high dose maternal toxicity accompanied by a reduction in weaning index and
reduced development of offspring in rats at approximately 4.3 times human
exposure. Teratology studies, performed in pregnant rats at approximately 4.3
times and pregnant rabbits at approximately 13 times human exposure did not
reveal any teratogenic effects.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.        PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.1      List of excipients</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tablet core</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Lactose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Microcrystalline cellulose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Magnesium stearate</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hydroxypropylcellulose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Croscarmellose sodium</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Colloidal hydrated silica</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Colloidal anhydrous silica</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Crospovidone</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Talc</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tablet coating</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Hypromellose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Ethylcellulose</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Iron oxide yellow (E172)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Triacetin</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Iron oxide black (E172)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.2      Incompatibilities</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Not applicable.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.3      Shelf life</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2 years.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For bottles: After first opening
use within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.4      Special precautions for
storage</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>This medicinal product does not
require any special storage conditions.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.5      Nature and contents of
container</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>(PVC/oPA/Alu)/Alu (desiccant
embedded) blisters of 14, 28, 84 tablets, calendar blisters of 28, 84 tablets
and perforated unit dose blisters of 28 x 1 tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>(PVC/oPA/Alu)/Alu blisters of 14,
28, 42 tablets, calendar blisters of 28 tablets and perforated unit dose
blisters of 28 x 1 tablets and multipacks of 84 (2 packs of 42) tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>HDPE bottle with polypropylene (PP)
screw cap closure with desiccant containing 28 or 84 tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:yellow'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6.6      Special precautions for
disposal</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>No special requirements.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>7.        MARKETING AUTHORISATION
HOLDER</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>Mylan
S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>117
Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>69
800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8.        MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/009</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/010</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/011</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/012</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/013</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/014</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/015</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/016</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/023</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/024</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/025</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/026</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/027</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/028</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Date of first authorisation: </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10.      DATE OF REVISION OF THE
TEXT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Detailed information on this
medicinal product is available on the website of the European Medicines Agency </span><span
lang=EN-GB><a href="http://www.emea.europa.eu/"><span style='font-family:"Times New Roman",serif;
color:windowtext'>http://www.ema.europa.eu</span></a></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>A.        MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.45pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>B.        CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.45pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>C.        OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.9pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;text-indent:-35.4pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>D.        <span
style='text-transform:uppercase'>conditions or restrictions with regard to the
safe and effective use of the medicinal product</span></span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>A.      MANUFACTURERS
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><u><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Name and address of the
manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Mylan Hungary Kft</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Mylan utca 1</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>H-2900 Komárom</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Hungary</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>McDermott Laboratories
Limited trading as Gerard Laboratories</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>35/36 Baldoyle
Industrial Estate</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Grange Road</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Dublin 13</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Ireland</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>The printed package
leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><a name="OLE_LINK2"><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>B.</span></b></a><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>      CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Medicinal product subject
to medical prescription.</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>C.      OTHER CONDITIONS
AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Periodic
Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>The requirements for submission of periodic safety
update reports for this medicinal product are set out in the list of Union
reference dates (EURD list) </span><span lang=EN-GB style='font-family:"Times New Roman",serif'>provided
for under Article 107c(7) of Directive 2001/83</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>/EC</span><span lang=EN-GB
style='font-family:"Times New Roman",serif'> and </span><span lang=EN-GB
style='font-family:"Times New Roman",serif'>any subsequent updates published on
the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;text-indent:-28.35pt;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>D.      CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT  </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><u><span lang=EN-GB style='font-family:
"Times New Roman",serif'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.5in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Risk
Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:28.35pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>The MAH shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;text-indent:-.25in;line-height:normal'><span lang=EN-GB
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>At
the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-10.35pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>LABELLING AND PACKAGE
LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:0in;text-align:center;
line-height:normal'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>A.
LABELLING</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>OUTER
CARTON (BLISTERS AND BOTTLES)</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 80&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>Film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=DE style='font-family:
"Times New Roman",serif;background:lightgrey;layout-grid-mode:line'>[Blisters]</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>14 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>28 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>42 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>84 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>28 x 1 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>28 film-coated tablets (calendar)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>84 film-coated tablets (calendar)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=DE style='font-family:
"Times New Roman",serif;background:lightgrey;layout-grid-mode:line'>[Bottles]</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>28 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>84 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>For bottles:</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> After first opening use
within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EU/1/17/1194/001</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/002</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/003</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/004</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/005</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/006</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/007</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/008</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/017</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/018</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/019</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/020</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/021</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>PC:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>NN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>OUTER
CARTON OF MULTIPACK (WITH BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 80&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
layout-grid-mode:line'>Multipack: 84 (2 packs of 42) film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/022</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>PC:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>INNER
CARTON OF MULTIPACK (WITHOUT BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 80&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>42 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Components of a multipack, cant be sold separately.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/022</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>PC:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>NN:</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE IMMEDIATE PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>BOTTLE
LABEL</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 80&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See the package leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>Film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>28 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>84 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>After first opening use within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EU/1/17/1194/007</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/008</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>MINIMUM
PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>[For calendar blisters only]:</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>MON</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>TUE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>WED</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>THU</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>FRI</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SAT</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SUN</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><b><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>OUTER
CARTON (BLISTERS AND BOTTLES)</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 120&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>Film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=DE style='font-family:
"Times New Roman",serif;background:lightgrey;layout-grid-mode:line'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>[Blisters]</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>14 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>28 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>42 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>84 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>28 x 1 film-coated
tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>28 film-coated tablets
(calendar)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>84 film-coated tablets
(calendar)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
background:lightgrey;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>[Bottles]</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>28 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>84 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>For bottles:</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> After first opening use
within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EU/1/17/1194/009</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/010</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/011</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/012</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/013</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/014</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/015</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/016</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/023</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/024</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/025</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/026</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/027</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>PC:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:lightgrey'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><span lang=EN-GB
style='font-family:"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>OUTER
CARTON OF MULTIPACK (WITH BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 120&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE style='font-family:"Times New Roman",serif;
layout-grid-mode:line'>Multipack: 84 (2 packs of 42) film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/028</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>PC:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>NN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>INNER
CARTON OF MULTIPACK (WITHOUT BLUE BOX)</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 120&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>42 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Components of a multipack, cant be sold separately.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.4pt;margin-bottom:0in;
margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>EU/1/17/1194/028</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>2D barcode carrying the
unique identifier included.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>PC:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>NN:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;background:white'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS
TO APPEAR ON THE IMMEDIATE PACKAGING </span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>BOTTLE
LABEL</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       STATEMENT
OF ACTIVE SUBSTANCE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Each tablet contains 120&nbsp;mg febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Also contains lactose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>See the package leaflet for further information.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>Film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>28 film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;color:black;background:#CCCCCC'>84 film-coated tablets</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For oral use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Keep out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>After first opening use within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=DE-AT style='font-family:
"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EU/1/17/1194/015</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>EU/1/17/1194/016</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>17.       UNIQUE
IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>18.       UNIQUE
IDENTIFIER  HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>MINIMUM
PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>BLISTERS</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><i><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg film-coated tablets </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>febuxostat</span><b><span lang=EN-GB style='font-family:
"Times New Roman",serif'> </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>EXP</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Lot</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:0in;margin-right:2.75pt'>

<p class=MsoNormal style='margin-bottom:0in;line-height:normal;border:none;
padding:0in'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.       OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>[<i>For calendar blisters only]:</i></span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>MON</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>TUE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>WED<br>
THU</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>FRI</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SAT</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>SUN</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 align=center style='margin-right:2.75pt;text-align:center'><span
lang=EN-GB>B. PACKAGE LEAFLET</span></h1>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Package leaflet:
Information for the patient</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat
Mylan 80&nbsp;mg film-coated tablets </span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat
Mylan 120&nbsp;mg film-coated tablets </span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>febuxostat</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Read all of this leaflet
carefully before you start taking this medicine because it contains important
information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you get any side effects talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>What
Febuxostat Mylan is and what it is used for</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>What
you need to know before you take Febuxostat Mylan</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>How
to take Febuxostat Mylan</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Possible
side effects</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>How
to store Febuxostat Mylan</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Contents
of the pack and other information</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>1.        What Febuxostat
Mylan is and what it is used for</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan tablets contain
the active substance febuxostat and are used to treat gout, which is associated
with an excess of a chemical called uric acid (urate) in the body. In some
people, the amount of uric acid builds up in the blood and may become too high
to remain soluble. When this happens, urate crystals may form in and around the
joints and kidneys. These crystals can cause sudden, severe pain, redness,
warmth and swelling in a joint (known as a gout attack). Left untreated, larger
deposits called tophi may form in and around joints. These tophi may cause
joint and bone damage.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan works by reducing
uric acid levels. Keeping uric acid levels low by taking Febuxostat Mylan once
every day stops crystals building up, and over time it reduces symptoms.
Keeping uric acid levels sufficiently low for a long enough period can also
shrink tophi.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan 120&nbsp;mg tablets
are also used to treat and prevent high blood levels of uric acid that may
occur when you start to receive chemotherapy for blood cancers.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>When chemotherapy is given, cancer
cells are destroyed, and uric acid levels increase in the blood accordingly,
unless the formation of uric acid is prevented.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan is for adults.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>2.       What you need
to know before you take Febuxostat Mylan </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Do not take Febuxostat
Mylan</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you are allergic to febuxostat or any of the other ingredients of this medicine
(listed in section 6).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Talk to your doctor before taking Febuxostat
Mylan:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you have or have had heart failure or heart problems</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you have or have had renal disease and/or serious allergic reaction to allopurinol
(a medication used for the treatment of Gout)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you have or have had liver disease or liver function test abnormalities</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you are being treated for high uric acid levels as a result of Lesch-Nyhan
syndrome (a rare inherited condition in which there is too much uric acid in
the blood)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>If
you have thyroid problems.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Should you experience allergic
reactions to Febuxostat Mylan, stop taking this medicine (see also section 4).
Possible symptoms of allergic reactions might be:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>rash
including severe forms (e.g. blisters, nodules, itchy, exfoliative rash), itchiness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>swelling
of limbs or face</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>difficulties
in breathing</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>fever
with enlarged lymph nodes</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>but
also serious life threatening allergic conditions with cardiac and circulatory
arrest. Your doctor might decide to permanently stop treatment with Febuxostat Mylan.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>There have been rare reports of
potentially life-threatening skin rashes (Stevens-Johnson Syndrome) with the
use of febuxostat, appearing initially as reddish target-like spots or circular
patches often with central blister on the trunk. It may also include ulcers in
the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes).
The rash may progress to widespread blistering or peeling of the skin.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you have developed
Stevens-Johnson Syndrome with the use of febuxostat, you must not be re-started
on Febuxostat Mylan at any time. If you develop a rash or these skin symptoms,
seek immediate advice from a doctor and tell them that you are taking this
medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you are having a gout attack at
the moment (a sudden onset of severe pain, tenderness, redness, warmth and
swelling in a joint), wait for the gout attack to subside first before starting
treatment with Febuxostat Mylan.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For some people, gout attacks may
flare up when starting certain medicines that control uric acid levels. Not
everyone gets flares, but you could get a flare-up even if you are taking Febuxostat
Mylan, and especially during the first weeks or months of treatment. It is
important to keep taking Febuxostat Mylan even if you have a flare, as Febuxostat
Mylan is still working to lower uric acid. Over time, gout flares will occur
less often and be less painful if you keep taking Febuxostat Mylan every day.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Your doctor will often prescribe
other medicines, if they are needed, to help prevent or treat the symptoms of flares
(such as pain and swelling in a joint).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>In patients with very high urate
levels (e.g. those undergoing cancer chemotherapy), treatment with uric
acid-lowering medicines could lead to the build-up of xanthine in the urinary
tract, with possible stones, even though this has not been observed in patients
being treated with febuxostat for Tumor Lysis Syndrome.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Your doctor may ask you to have
blood tests to check that your liver is working normally.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Children and adolescents</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not give this medicine to
children under the age of 18 because the safety and efficacy have not been
established.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Other medicines and Febuxostat
Mylan</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor or pharmacist if
you are taking, have recently taken or might take any other medicines,
including medicines obtained without a prescription.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>It is especially important to tell
your doctor or pharmacist if you are taking medicines containing any of the
following substances as they may interact with Febuxostat Mylan and your doctor
may wish to consider necessary measures:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Mercaptopurine
(used to treat cancer)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Azathioprine
(used to reduce immune response)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>Theophylline
(used to treat asthma)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Pregnancy and
breast-feeding</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>It is not known if febuxostat may
harm your unborn child. Febuxostat Mylan should not be used during pregnancy.
It is not known if febuxostat may pass into human breast milk. You should not
use Febuxostat Mylan if you are breast-feeding, or if you are planning to
breast-feed.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you are pregnant or
breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor or pharmacist for advice before taking this medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Driving and using
machines</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Be aware that you may experience
dizziness, sleepiness, blurred vision and numbness or tingling sensation during
treatment and should not drive or operate machines if affected.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Febuxostat Mylan
contains lactose</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan tablets contain
lactose (a type of sugar). If you have been told that you have an intolerance
to some sugars contact your doctor before taking this medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h1 style='margin-right:2.75pt'><span lang=EN-GB>3.       How to take Febuxostat
Mylan</span></h1>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Always take this medicine exactly
as your doctor has told you. Check with your doctor or pharmacist if you are
not sure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
usual dose is one tablet daily. The back of the calendar blister pack is marked
with the days of the week to help you check that you have taken a dose each
day.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>The
tablets should be taken by mouth and can be taken with or without food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Gout</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan is available as
either an 80</span><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>mg tablet or a 120&nbsp;mg
tablet. Your doctor will have prescribed the strength most suitable for you.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Continue to take Febuxostat Mylan
every day even when you are not experiencing gout flare or attack.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Prevention and treatment
of high uric acid levels in patients undergoing cancer chemotherapy</span></i></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan is available as a
120&nbsp;mg tablet.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Start taking Febuxostat Mylan two
days before chemotherapy and continue its use according to your doctors
advice. Usually treatment is short-term.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.85pt;margin-bottom:
0in;margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB style='font-family:"Times New Roman",serif'>If you
take more Febuxostat Mylan than you should</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.85pt;margin-bottom:
0in;margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.85pt;margin-bottom:
0in;margin-left:0in;line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>In the event
of an accidental overdose ask your doctor what to do, or contact your nearest
accident and emergency department.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>If you forget to take Febuxostat
Mylan</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;text-align:justify;line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>If you miss a dose of Febuxostat
Mylan take it as soon as you remember unless it is almost time for your next
dose, in which case miss out the forgotten dose and take your next dose at the
normal time. Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>If you stop taking Febuxostat
Mylan</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not stop taking Febuxostat Mylan
without the advice of your doctor even if you feel better. If you stop taking Febuxostat
Mylan your uric acid levels may begin to rise and your symptoms may worsen due
to the formation of new crystals of urate in and around your joints and
kidneys.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you have any further questions
on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.        Possible side
effects</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Like all medicines, this medicine
can cause side effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Stop taking this medicine and
contact your doctor immediately or go to an emergency department nearby if the
following rare (may affect up to 1 in 1,000 people) side effects occur, because
a serious allergic reaction might follow:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>anaphylactic
reactions, drug hypersensitivity (see also section 2 Warnings and
precautions)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>potentially
life-threatening skin rashes characterised by formation of blisters and
shedding of the skin and inner surfaces of body cavities, e.g. mouth and
genitals, painful ulcers in the mouth and/or genital areas, accompanied by
fever, sore throat and fatigue (Stevens- Johnson Syndrome/ Toxic Epidermal
Necrolysis), or by enlarged lymph nodes, liver enlargement, hepatitis (up to
liver failure), raising of the white-cells count in the blood (drug reaction
with eosinophilia and systemic symptoms-DRESS) (see section 2)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>generalised
skin rashes</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Other side effects which are not
mentioned above are listed below.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Common side effects </span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(may affect up to 1 in
10 people) are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>abnormal
liver test results</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>diarrhoea</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>headache</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>rash
(including various types of rash, please see below under uncommon and rare
sections)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>nausea</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>increase
in gout symptoms</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>localised
swelling due to retention of fluids in tissues (oedema)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Uncommon side effects </span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(may affect up to 1 in
100 people) are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>decreased
appetite, change in blood sugar levels (diabetes) of which a symptom may be excessive
thirst, increased blood fat levels, weight increase</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>loss
of sex drive</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>difficulty
in sleeping, sleepiness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>dizziness,
numbness, tingling, reduced or altered sensation (hypoesthesia, hemiparesis or paraesthesia),
altered sense of taste, diminished sense of smell (hyposmia)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>abnormal
ECG heart tracing, irregular or rapid heartbeats, feeling your heart beat
(palpitation)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>hot
flushes or flushing (e.g. redness of the face or neck), increased blood
pressure, bleeding (haemorrhage, seen only in patients taking chemotherapy for
blood disorders)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>cough,
shortness of breath, chest discomfort or pain, inflammation of nasal passage
and/or throat (upper respiratory tract infection), bronchitis</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>dry
mouth, abdominal pain/discomfort or wind, heartburn/indigestion, constipation,
more frequent passing of stools, vomiting, stomach discomfort</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>itching,
hives, skin inflammation, skin discoloration, small red or purple spots on the
skin, small, flat red spots on the skin, flat, red area on the skin that is
covered with small confluent bumps, rash, areas of redness and spots on the
skin, other type of skin conditions</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>muscle
cramp, muscle weakness, pain/ache in muscles/joints, bursitis or arthritis
(inflammation of joints usually accompanied by pain, swelling and/or stiffness),
pain in extremity, back pain, muscle spasm</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>blood
in the urine, abnormal frequent urination, abnormal urine tests (increased
level of proteins in the urine), a reduction in the ability of the kidneys to
function properly</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>fatigue,
chest pain, chest discomfort</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>stones
in the gallbladder or in bile ducts (cholelithiasis)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>increase
in blood thyroid stimulating hormone (TSH) level</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>changes
in blood chemistry or amount of blood cells or platelets (abnormal blood test
results)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>kidney
stones</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>erectile
difficulties</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Rare side effects </span></b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>(may affect up to 1 in
1,000 people) are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>muscle
damage, a condition which on rare occasions can be serious. It may cause muscle
problems and particularly, if at the same time, you feel unwell or have a high
temperature it may be caused by an abnormal muscle breakdown. Contact your
doctor immediately if you experience muscle pain, tenderness or weakness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>severe
swelling of the deeper layers of the skin, especially around the lips, eyes,
genitals, hands, feet or tongue, with possible sudden difficult breathing</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>high
fever in combination with measles-like skin rash, enlarged lymph nodes, liver
enlargement, hepatitis (up to liver failure), raising of the white-cells count
in the blood (leukocytosis, with or without eosinophilia)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>reddening
of the skin (erythema), rash in various types (e.g. itchy, with white spots,
with blisters, with blisters containing pus, with shedding of the skin,
measles-like rash), widespread erythema, necrosis, and bullous detachment of
the epidermis and mucous membranes, resulting in exfoliation and possible
sepsis (Stevens-Johnson Syndrome/Toxic epidermal necrolysis)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>nervousness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>feeling
thirsty</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>ringing
in the ears</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>blurred
vision, change in vision</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>hair
loss</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>mouth
ulceration</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>inflammation
of the pancreas: common symptoms are abdominal pain, nausea and vomiting</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>increased
sweating</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>weight
decrease, increased appetite, uncontrolled loss of appetite (anorexia)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>muscle
and/or joint stiffness</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>abnormally
low blood cell counts (white or red blood cells or platelets)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>urgent
need to urinate</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>changes
or decrease in urine amount due to inflammation in the kidneys
(tubulointerstitial nephritis)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>inflammation
of the liver (hepatitis)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>yellowing
of the skin (jaundice)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>liver
damage</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>increased
level of creatine phosphokinase in blood (an indicator of muscle damage)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Reporting of side
effects</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you get any side effects, talk
to your doctor or pharmacist. This includes any possible side effects not
listed in this leaflet. You can also report side effects directly via the national
reporting system listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-family:"Times New Roman",serif;color:windowtext'>Appendix V</span></a></span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>. By reporting side
effects you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5.        How to store Febuxostat
Mylan</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Keep this medicine out of the sight
and reach of children.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not use this medicine after the
expiry date which is stated on the packaging after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>For bottles, after first opening
use within 180 days</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>This medicine does not require any
special storage conditions.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.        Contents of
the pack and other information</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>What Febuxostat Mylan
contains</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The active substance is febuxostat.
Each tablet contains 80&nbsp;mg or 120&nbsp;mg of febuxostat.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>The other ingredients are:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Tablet core</span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>: lactose (see section
2, Febuxostat Mylan contains lactose), microcrystalline cellulose, magnesium
stearate, hydroxypropylcellulose, croscarmellose sodium, colloidal hydrated silica,
colloidal anhydrous silica, crospovidone and talc.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Film-coating: </span></i><span
lang=EN-GB style='font-family:"Times New Roman",serif'>hypromellose, titanium
dioxide (E171), ethylcellulose, iron oxide yellow (E172), triacetin and iron oxide
black (E172).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>What Febuxostat Mylan
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan film-coated
tablets are yellow, capsule shaped, biconvex tablets. The 80&nbsp;mg tablets
are marked with M on one side of the tablet and FX3 on the other side. The 120&nbsp;mg
tablets are marked with M on one side of the tablet and FX4 on the other side.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan 80&nbsp;mg and 120&nbsp;mg
film-coated tablets are available in blister packs of 14, 28, 42 and 84
tablets, calendar blister packs of 28 and 84 tablets, and perforated unit dose
blister packs of 28 x 1 tablets and in multipacks of 84&nbsp;film-coated
tablets comprising 2 packs, each containing 42&nbsp;film-coated tablets.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Febuxostat Mylan 80 mg and 120&nbsp;mg
film-coated tablets are available in plastic bottles of 28 and 84 tablets. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Marketing Authorisation
Holder</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Mylan S.A.S.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>117 Allee des Parcs</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>69 800 Saint Priest</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Manufacturer</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Mylan Hungary Kft</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Mylan utca 1</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>H-2900 Komárom</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>Hungary</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>McDermott Laboratories Limited
trading as Gerard Laboratories</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>35/36 Baldoyle Industrial Estate</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>Grange Road</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>Dublin 13</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif;background:lightgrey'>Ireland</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>For any information about this medicine, please
contact the local representative of the Marketing</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Authorisation Holder.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:3.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><b><span
  lang=EN-GB>België/Belgique/Belgien</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><span
  lang=EN-GB>Mylan bvba/sprl</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><span
  lang=EN-GB>Tél/Tel: + 32 (0)2 658 61 00</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><b><span
  lang=EN-GB>Lietuva</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><span
  lang=EN-GB>BGP Products UAB</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><span
  lang=EN-GB>Tel: +370 5 205 1288</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt;page-break-after:avoid'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:71.25pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:71.25pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&#1052;&#1072;&#1081;&#1083;&#1072;&#1085;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&#1058;&#1077;&#1083;:
  +359 2 44 55 400</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:71.25pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan
  bvba/sprl</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 32 (0)2
  658 61 00</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>(Belgique/Belgien)</span></p>
  </td>
 </tr>
 <tr style='height:49.1pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.1pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>&#268;eská
  republika</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan
  Pharmaceuticals.s.r.o.</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel:
  +420&nbsp;222 004 400</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.1pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan EPD
  Kft</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 36 1&nbsp;465
  2100</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan AB</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tlf: + 46
  855 522 750 </span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>(Sverige)</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>V.J.
  Salomone Pharma Ltd</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 356
  21 22 01 74</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan dura
  GmbH </span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +
  49-(0) 6172 888 01</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan BV</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +31
  (0)20 426 3300</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>BGP
  Products Switzerland GmbH Eesti filiaal</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 372
  6363 052</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan AB</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 46
  855 522 750</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>(Sverige)</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;
  </span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Generics
  Pharma Hellas &#917;&#928;&#917; </span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&#932;&#951;&#955;:
  +30 210 993 6410 </span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Arcana
  Arzneimittel GmbH</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: </span>+43
  1 416 2418</p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>España</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan Pharmaceuticals,
  S.L</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: </span><span
  lang=EN-GB>+ 34 900 102 712</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan Healthcare
  Sp. z.o.o.</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 48
  22 546 64 00</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>France</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan S.A.S</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +33 4
  37 25 75 00</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan, Lda.</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 351
  21 412 72 56</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan
  Hrvatska d.o.o.</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +385 1
  23 50 599</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>România</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>BGP
  Products SRL</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +40
  372 579 000</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan
  Ireland</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +353
  (0) 87 1694982</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>GSP Proizvodi d.o.o.</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 386
  1 236 31 85</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Ísland</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan AB</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 46
  855 522 750</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>(Svíþjóð)</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Slovenská
  republika</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan
  s.r.o.</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Tel: </span><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>+421&nbsp;2 32 199 100</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan S.p.A</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 39
  02 612 46921</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><b><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><strong><span lang=EN-GB
  style='color:black;border:none windowtext 1.0pt;padding:0in;background:white;
  font-weight:normal'>Mylan OY</span></strong></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'>Puh/Tel: +358 20 720 9555</p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Pharmaceutical
  Trading Co. Ltd.</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&#932;&#951;&#955;:
  + 357 99403969</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Mylan AB </span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: + 46
  855 522 750</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>BGP
  Products SIA</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Tel: +371
  676 055 80</span></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MGGTextLeft style='margin-right:2.75pt'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MGGTextLeft style='margin-right:2.75pt'><span lang=EN-GB>Generics
  [UK] Ltd</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
  0in;margin-left:0in;line-height:normal'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Tel: +44 1707 853000</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>This leaflet was last
revised in</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Other sources of
information</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Detailed information on this
medicine is available on the European Medicines Agency website</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:2.75pt;margin-bottom:
0in;margin-left:0in;line-height:normal;text-autospace:none'><span lang=EN-GB><a
href="http://www.ema.europa.eu."><span style='font-family:"Times New Roman",serif'>http://www.ema.europa.eu.</span></a></span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:2.75pt;
margin-bottom:0in;margin-left:0in;text-align:center;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

</div>

</body>

</html>
